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APIs (Active Pharmaceutical Ingredients) are the biological active 
compounds of pharmaceutical formulations. APIs are molecules able to 
induce a biological effect, playing a very important role for the world public 
health and, for this reason, they are employed for the prevention or 
eradication of some pathologies and diseases. 
Different types of APIs are available on the market, starting from older 
synthetic to newer biotechnological and bio-fermentation drugs. As a 
result, the global market of these compounds reaches $182.2 billion in 
2019 but future predictions are projecting the market over $300 billion by 
20251,2. These important data are closely related to all facilities in the world 
dedicated to the synthesis or preparation of all starting materials and 
intermediates needed for the production of APIs. 
Thanks to the continuous worldwide request of these compounds, 
pharmaceutical companies are involved in the development of new and 
innovative drugs for the treatment of on chronic, cardiovascular and cancer 
diseases2, and many other pathologies.  
The above cited three classes have an important impact on the drug 
market but nowadays, the development of news HP-APIs (High Potent-
APIs) facilities, related to the high-potent drugs production, the recent 
production of biopharmaceutical compounds and the continuous growth of 
the market of generics, are leading the big pharma into new important 
market area, and, for these reasons, pharmaceutical companies are 
investing significant technological and economical resources for the 




APIs can be produced by three different industries: 
 
Pharmaceutical Innovators are focused on introducing new APIs on the 
market. Once the APIs is launched on the market, its production may be 
outsourced to contract manufacturers, the latter being in charge for the 
production of batches of specific APIs. When intellectual property (IP) on 
an API expires, it becomes a “generic API” and other companies enter in 
this market to develop cheaper alternative production processes of the 
API. Nevertheless, the quality of the APIs must not to be inferior of the 
original branded compound. During the synthesis, all pending patented 
processes must be bypassed with the main goal identified in finding a 
cheaper production cost while maintaining the quality of the final product. 
The manufacturing of APIs is strictly supervised by specific government 
agencies, different for each country but with the aim to control the quality 
standard of GMP rules (Good Manufacturing Practices). For example, 











and EMA (European Medicine Agency) are the government agency 
operating in Italy, U.S and Europe, respectively.  
APIs must meet different quality requirements such as:  
- structural identification (NMR, HPLC retention time, single-crystal X-
ray or powder X-ray),  
- purity assessment (HPLC purity, residual solvents by GC, water 
content, presence of heavy metals, etc),  
- appearance (colour and morphology),  
- physico-chemical properties (pH, melting point),  
- solid-state properties (crystal form, eventual polymorphs, solvates). 
All these parameters are well discussed in the ICH guide-lines3. ICH 
(International Council for Harmonization of Technical Requirements for 
Pharmaceuticals for Human Use) defines a series of tests and procedure 
that pharma company must follow for the correct production and 
characterisation of the product. Generally, ICH are divided in four 
categories: 
 Quality guidelines 
 Safety guidelines 
 Efficacy guidelines  
 Multidisciplinary guidelines 
 
For example, Q3C(R6) guideline refers to possible residual solvents in the 
final API, with corresponding limit (PDE: Permitted Daily Exposure), or Q1A 
– Q1F guidelines refer to the stability of API. A very important ICH 
guidelines is Q3D(R1) that refers to the possible amount of elements like 
Cu, Pb, Pd, Pt, Sn, Rh and many others, setting a very low limit3. 
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After all these considerations regarding the quality and characteristics of 
the APIs, the main goal of a pharmaceutical company is related to the 
effective production of active compounds.   
APIs manufacturing requires a robust synthetic process in order to 
minimize or reduce the possible problems during the production, especially 
when reaching industrial scale. 
Moreover, particular attention is focused on the factors influencing the total 
cost of the final API, including the price of the starting materials, the 
number of synthetic steps, yield, production costs, catalysts (if present) and 
many others. 
For these reasons, the pharmaceutical industries employ a lot of scientific 
and technological resources with the aims to reduce the production costs, 
increase the total yield in order to increase the total profit. 
In order to develop a robust synthetic process, a huge number of resources 
are employed by pharma industry devoted to the identification of the best 
reaction conditions. To this purpose, a general scheme of process is 





Scheme 1.1: General scheme of process development 
 
The first step is the R&D laboratory, in which the desired API is designed 
and synthesized ab initio or following literature procedures taken from 
patents or articles. In this phase, the attention is paid to avoid inappropriate 
synthetic procedures such as the use of hazardous reagents or 
combination of them and dangerous operative conditions. 






















During this step, all issues related to the synthetic route such as production 
costs, starting materials and yield, must be solved in order to develop a 
robust and cheap process. After these identifications, the synthetic process 
can be produced in different scales following kilogram or bulk scale 
reaching the final sales stage. 
The main goal of the pharmaceutical industry is to decrease the cost 
related to an API production. Different areas are closely related to each 
other and affect positively or negatively the total cost. This relationship is 
showed in Scheme 1.2. 
 
Scheme 1.2: Total cost relationships 
As showed in scheme 1.2, four issues can be addressed in order to 
decrease the total cost: 
 Synthetic process 
 Starting material 
 Auxiliary operations 













The correct synthetic process is essential for the manufacturing of APIs. 
Several efforts are devoted to the identification of the best synthesis. One 
possible strategy is based on the reduction and optimisation of the 
synthetic steps. After the screening of the new and possible synthetic 
processes, one or two synthetic pathways are identified as the best.  
Then, availability and price of the corresponding starting materials are to 
be defined as they play a crucial role in the synthetic processes. Much work 
is dedicated to identify the best supplier with the optimal features in terms 
of purity and cost. After this step, the reaction conditions are screened, in 
particular: 
- Reagents 
- Solvents (type and amount) 
- Catalyst, if needed 
- Operative conditions (concentrations, temperature, pressure, inert 
atmosphere) 
In addition, calorimetric analysis is performed with the aim to detect the 
safety profile of the reaction analysing the energy produced during the 
reaction. After this study, the obtained parameters are used to define the 
correct reaction protocol: which reagent is added first, optimal 
concentration etc. 
After this screening, work-up procedures are studied focusing the attention 
on the best and simple procedure to apply to obtain the desired product. 
Then, the complete analytical profile of the whole process is followed 
through HPLC/GC, NMR, and any other analytical technique that could be 
suitable to give full snapshot on the purity profile of the API.  
The R&D working on the above cited steps, gives as a result a process 
that is nearly always completely different from the original synthesis of the 
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API applied by medicinal chemistry laboratories. The process is almost 
mature and ready to be scaled up to the industrial production. 
The API can then be transferred in the industrial plant, classified on the 
base of the capacity of the manufacturing plant itself: 
- Pilot plant 
- Manufacturing plant  
In the pilot plant, the synthesis starts to be applied on a wider scale, 
meaning hundred grams to kilogram-scale. This allows to identify scale-
related problems and to solve them promptly. Once the process works on 
this scale reproducibly, it can be transferred on the final, large scale 
manufacturing plant. The latter can span from slightly more than a pilot 
plant, for high-potency specialty APIs, to very large 15-20000 L reactors 
with proportionally larger dedicated plants. 
After these considerations on to the synthetic process and its costs, 
another important issue must be considered: the solid-state properties of 
the final APIs. The correct crystalline form is fundamental for the final 
formulation of the APIs because different crystalline forms possess 
different physico-chemical properties without altering the chemical 
properties of the APIs.  
The presence of different crystal forms of the same compound is called 
polymorphism. The compound may show different crystal forms as a result 
of different crystal packing (“packing polymorphism”) or arising from 
different molecular conformations (“conformational isomerism”). Moreover, 
the crystal may contain additional components, giving salts, solvates and 
cocrystals, collectively indicated as pseudopolymorphs. 
Different pseudopolymorphs are present and were classified by Grothe et 






These three classes are further divided in to seven sub-classes, obtained 
by combination of different cases: 
- True solvate (no ions) 
- True salt (only ions) 
- True cocrystal (only conformer) 
- Salt solvate (no conformer) 
- Cocrystal solvate (no ions) 
- Cocrystal salt (no solvate) 
- Cocrystal salt solvate  
This important classification is a useful tool for the correct identification of 
the final crystalline form of the APIs. The presence of different crystal form 
can alter properties such as the solubility5 or dissolution rate.6 The “actual” 
crystalline form can be ascertained through different analytical methods 
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Chapter 2: Outline 









2.1. Outline of the Thesis 
 
APIs (Active Pharmaceutical Ingredients) are compounds able to induce a 
biological effect interacting with specific targets. They are employed as 
tools for the treatment of infections, cardiovascular disease, cancer 
disease and many other pathologies, improving the global health. 
APIs employed in the clinical practice are still the subject of a continue and 
vibrant research, finalised to the development of the synthetic process and 
to the comprehensive knowledge of their solid-state properties and the 
potential interaction with other excipients. 
APIs require robust chemical processes in order to meet the requirements 
for a convenient industrial production and to satisfy the market requests. 
For these reasons, several efforts are devoted to the identification of the 
best synthetic process with the minimum number of synthetic steps and 
the maximum yield. 
This PhD program is focused on different aspects of the work mentioned 
above. In particular, we concentrated our attention on the screening of 
alternative synthetic processes and on studying the solid-state chemistry 






Scheme 2.1: PhD program scheme  
 
In Chapter 3, a screening of alternative synthetic processes and reactions 
devoted to the preparation of the API maropitant citrate monohydrate, is 
described.  
Chapter 4 reports on the unexpected reactivity of secondary amines and 
vanillin. 
Chapter 5 describes the approach to the preparation of a supported 
catalyst (DMAP), with the first-time derivatisation of this important 




















In Chapter 6, 7 and 8, the polymorphism of selected APIs (gepirone 


























Emesis and vomiting, induced by motion sickness, are two important 
syndromes in animals that can change their normal life. Emesis can be 
induced by several pathologies such as gastro-enteritis, pancreatitis, 
dietary problems and many others, but it is, also, correlated with the use of 
anti-cancer drugs1. It is regulated by a series of nuclei located in different 
parts of the body as well as in a specific zone called chemoreceptor trigger 
zone (CTZ).2 
Otherwise, motion sickness induces vomiting by travelling by the car, boat, 
planes or other motion-related stimuli.3 Generally, this condition is reported 
in puppies and young animals but decreasing during the aging.  
In order to treats and solve these problems, Pfizer developed a new drug 
called maropitant (trade mark name Cerenia®). Maropitant is used for the 
treatment of emesis, vomiting induced by motion sickness, and it is a 
veterinary use-only, especially in dogs and cats.  
 
 
Figure 3.1: Maropitant free base 
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Maropitant is a neurokinin-1 (NK-1) receptor antagonist and its mechanism 
of action consists of binding and blocking the substance P, an endogenous 
peptide able to interact with NK-1 receptor inducing vomiting4. 
It was approved by FDA in 2007 for dogs then in 2012 for cats and it is 
commercialized as citrate monohydrate (Figure 3.2): 
 
Figure 3.2: Maropitant citrate monohydrate 
Maropitant shows an additional potential anti-inflammatory activity, and it 
was demonstrated by researcher group of Atsushi Tsukamoto that 
reported this anti-inflammatory activity in the treatment of acute 
pancreatitis5 without losing the main antiemetic activity. 
Maropitant is commercially available in different pharmaceutical forms 
such as tablets, with different dosages (16, 24, 60 or 160 mg of API), or 
injectable solution (10 mg/mL).  
The IUPAC name of the free base of maropitant is (2S,3S)-2-benzhydryl-
N-(5-tert-butyl-2-methoxybenzyl)-quinuclidine-3-amine, highlighting the 
different structural portions: 
- a bicyclic disubstituted quinuclidine moiety,  
- a benzhydryl group on C-2 
- a 2-methoxy-5-t-butylbenzylamine residue on C-3. 
The carbon atoms C-2 and C-3 are stereocenters, their substituents having 
relative stereochemistry cis and absolute configuration (2S,3S).  
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The API is the citrate salt of Maropitant free base, isolated as the citrate 
monohydrate. It is a white solid and it is characterised by the presence of 
two polymorphic forms named “A” and “B”. The form A is more stable than 
B but both forms are suitable for treating emesis in animals.6 
 
 
3.2. Original Synthesis 
Maropitant is synthesised following a long and tedious synthetic process 





Scheme 3.1: Original synthesis of maropitant
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Maropitant is synthesised in 8 synthetic steps starting from the 
commercially available starting material, 3-quinuclidinone hydrochloride. 
The length of the synthesis prompted us to investigate possible 
improvements or alternatives, starting from a simple retrosynthetic 
analysis. This approach led us to the identification of two different 
strategies: 
- Different approaches for the building of (2S)-2-benzhydryl-3-
quinuclidinone (blue circle, Scheme 3.2) and 
- Reductive amination for the set-up of the benzylamine residue (red 
circle, Scheme 3.2) 
 
 














3.3. Direct Alkylation 
(2S)-2-Benzhydryl-3-quinuclidinone (7) is a key intermediate in this 
process. Moreover it is involved in the synthesis of several correlated 
bioactive molecules, such as L703606 (NK-1 antagonist)6,11 and 3-amino-
2-benzhydrylquinuclidine (diuretic)12 (Scheme 3.3). 
 
Scheme 3.3: Central role of (2S)-2-benzhydryl-3-quinuclidinone (7) 
 
Usually, this intermediate, is prepared following established literature 
methods8,9,13. The first step involves a crossed-aldol condensation 
between 3-quinuclidinone hydrochloride and benzaldehyde in the 
presence of sodium hydroxide as base. The enone is isolated in nearly 
quantitative yield and this step does not need further optimisation.  
A conjugate addition of phenylmagnesium bromide on the Δα,β unsaturated 
system leads to the desired product. A dynamic resolution process with L-
tartaric acid lead to the intermediate 6. After treatment with an opportune 

























Scheme 3.4: Literature synthesis for the preparation of 2-benzhydryl-3-
quinuclidinone 
 
This second step is affected by the presence of by-products and low 
conversion of the starting material, limiting the yield less than 50%. 
One of the main byproducts arising from the use of the Grignard reagent 
during the conjugate addition, arise from the double attack on the enone 
moiety (11, Figure 3.3): 
 




For these reasons, during my PhD program, we focused our attention on 
an alternative synthetic process for the preparation of the important key 
intermediate (2S)-2-benzhydryl-3-quinuclidinone, avoiding as much as 
possible the formation of byproducts and improving the yield of the 
preparation.  
 
3.3.1. Heck – arylation approach 
Different synthetic approaches to (2S)-2-benzhydryl-3-quinuclidinone were 
investigated, maintaining 3-quinuclidinone hydrochloride as the starting 
material due to its convenient price and wide availability. 
The first attempt was the introduction of the second aryl group through an 
alternative synthetic procedure, identified in the Mizoroki – Heck 
arylation14. In this reaction, the arylation mechanism is shifted from a 
conjugated addition to a transition metal-catalysed addition, with the enone 
compound as the acceptor and iodobenzene as the arylating agent. The 
reaction is run in the presence of tetrabutylammonium bromide, 








Unfortunately, no evidence of the formation of the desired arylated product 
was observed, so we moved our attention on a completely different 
approach. 
 
3.3.2. Stevens Rearrangement approach 
The second strategy was based on the Stevens rearrangement. This 
rearrangement converts a quaternary ammonium salt into corresponding 
tertiary amine, through different sigmatropic rearrangements. 
In general, the corresponding ylides, can evolve in two distinct pathways:  
1) [1,2] shift of an ammonium ylide to the corresponding tertiary amine, 
and this pathway is called Stevens [1,2] rearrangement15 
2) [2,3] shift of an ammonium ylide (13) to the corresponding tertiary 
amine (14) mediated by the presence of allylic substituent, and in 
this case, this pathway is called Stevens [2,3] rearrangement16, also 
well known as Sommelet – Hauser rearrangement17 (Scheme 3.6). 
 
Scheme 3.6: Stevens [2,3] rearrangement 
 
Both rearrangements take place in basic condition.  
The product obtained by [1,2] rearrangement can be formed following two 
different mechanisms, as reported by Ollis et al18 in 1983: 
a- Concerted [1,2] sigmatropic rearrangement, with retention of 
configuration of the migrating group16, 
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b- Homolysis of the C-N bond (17) between the migrating group and 
the quaternary nitrogen atom, to generate a radical pair that rapidly 
evolves to the corresponding product. 
The first example of [1,2] rearrangement was reported by Stevens15 in 
1928. The first step was the reaction between 2-(N,N-dimethylamino)-1-
phenylethanone (20) and benzylbromide (21), leading to a quaternary 
ammonium salt (22, Scheme 3.7):  
 
 
Scheme 3.7: Synthesis of the quaternary ammonium salt 
 
The second step runs in the presence of a base or, if necessary, a strong 
base. The latter generates the intermediate ylide evolving spontaneously 
to the corresponding amine, 2-(N,N-dimethylamino)-1,3-diphenylpropan-1-
one (24) (Scheme 3.8): 
 
 
Scheme 3.8: Stevens rearrangement of the quaternary ammonium salt 
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This specific 1,2 electrophilic rearrangement requires the formation of the 
corresponding carbanion (ylide) as the intermediate. If no others electron 
withdrawing groups are present, except the quaternary ammonium group, 
strong bases are required, for example (Na, PhLi, fused KOH). 
The presence of a disubstituted carbon atom in  to the tertiary amine in 
2-benzhydryl-3-quinuclidinone prompted us to investigate the applicability 




Scheme 3.9: Retrosynthetic analysis of 2-benzhydryl-3-quinuclidinone 
involving a Stevens rearrangement 
At first, we synthesized the corresponding quaternary ammonium salt 
starting from 3-quinuclidinone and benzhydryl bromide, following the 
procedure reported in patent EP 0785198 A119 (Scheme 3.10). The 
quaternary salt is obtained in 93% yield. 
 
 
Scheme 3.10: Preparation of the quaternary quinuclidinium salt  
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Then, the Stevens [1,2] rearrangement was tested in the presence of 
different combinations base/solvent (Scheme 3.11). 
 
Scheme 3.11: Stevens [1,2] rearrangement 
 
The combinations base/solvent investigated for this specific 
rearrangement are summarized in Table 3.1. 
 
 Base Solvent 
#1 DBU Acetonitrile 
#2 t-BuO-K+ t-butanol 
#3 NaOH water 
 
Table 3.1: different trials of Stevens rearrangement 
 
All the reactions were run at room temperature. After 16 hours at room 
temperature, no evidence of the formation of the desired product was 
observed and for this reason all three reactions were warmed at 60°C. 
Reaction #2 and #3 did not proceed even after additional 16 hours at 60 




The NMR analyses of the product of reaction #1 were not compatible with 
the expected structure. Careful analysis of the NMR spectra allowed to 
identify the product as the compound resulting from a competing Sommelet 
– Hauser [2,3] rearrangement (27, Scheme 3.12). 
 
 
Scheme 3.12: Sommelet-Hauser rearrangement  
 
The absence of products from the expected Stevens rearrangement 
suggests that the intermediate ylide reacts through the Sommelet-Hauser 
mechanism with complete selectivity. This approach was then abandoned. 
 
3.3.3. Direct Benzhydrylation  
We investigated the direct alkylation of 3-quinuclidinone using 
“benzhydrylating agents”, and taking advantage of the easy enolisation of 
the starting aminoketone.  
For this alternative synthetic approach, three different benzhydrylating 
agents were identified, in detail: benzophenone (28), 
dimethoxydiphenylmethane (29), diphenylmethanol (30), and 





Scheme 3.13: Approaches to the introduction  
of the benzhydryl(idene) moiety 
 
Different combinations bases/solvents were investigated in order to 
perform these reactions. All the attempts are reported in Table 3.2. 
 
Alkylating agent Base Solvent T (°C) Result 
Benzophenone 
DBU 
CH3CH2OH 60 °C 
NR 
DABCO NR 
L-proline/ NaOH NR 




25 °C  
to 60 °C 
NR 
Diphenylmethanol - CF3COOH 60 °C NR 
Table 3.2: Summary of reactions conditions 
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Unfortunately, applying the previous reported procedures, no evidence of 
the formation of the desired products was observed, probably related to 
the low reactivity of the benzhydrylating agents. The poor results obtained 
with this approach led us to the investigation of an alternative 
benzhydrylation method, enhancing the reactivity of the starting material 
through the formation of the corresponding silyl-enol ether. 
 
3.3.4. Silyl-enol ether approach 
 
The starting material (3-quinuclidinone), is known to form the 
corresponding enolate quite easily (32, Figure 3.4), as demonstrated by 




Figure 3.4: Base promoted formation of the 3-quinuclidinone enolate 
 
Silylating agents (SAs) can trap the enol with the formation of the 
corresponding silyl enol ether derivatives (33), as reported in (scheme 
3.14). This intermediate, can be reacted with alkylating agent, in general 





Scheme 3.14: Trapping of the enolate with silylating agents 
 
 
Scheme 3.15: Lewis acid-catalysed alkylation of silyl enol ether 
 
For the investigation of this approach, the starting material 3-
quinuclidinone was treated with a suitable base leading to the 
corresponding enol form, trapped by a suitable silylating agent giving the 
silyl enol ether intermediate. The latter was treated with an alkylating agent 
in presence of Lewis acid. In this investigation, two diphenylmethylating 
agents were used, in order to have a direct access to the desired product. 
In detail, we used for this screening bromodiphenylmethane and 
chlorodiphenylmethane. 
In order to perform this synthetic approach, we screened different bases, 























BF3 Et2O NR 
TiCl4 NR 
DBU 
THF dry/ 40°C 
ZnCl2 
NR 





DCM dry/ 40°C NR 
t-BuO-K+ THF dry/ R.T ZnCl2 NR 
… 
… THF dry/ R.T ZnCl2 
NR 
t-BuO-K+ NR 
… HMDS/TMSCl MeCN/ R.T. ZnCl2 NR 
… 
TMSOTf DCM dry/ Reflux ZnCl2 
NR 
DBU 70% 
t-BuO-K+ … THF dry/ R.T ZnCl2 Chlorodiphenylmethane NR 




After this screening, the desired product 2-benzhydryl-3-quinuclidinone 
was obtained only using the following two combinations: 
- TMSCl/ DBU/ DCM dry/ ZnCl2  
- TMSOTf/ DBU/ DCM dry/ ZnCl2 
 
In particular, the silyl-enol-ether (35) intermediate described in the first 
combination system, was synthesized following the reported literature by 
Taniguchi et al20, using trimethylsilylchloride and DBU as silylating agent 
and base, respectively. The resulting solution was added to a mixture 




Scheme 3.16: Alkylation through SN1 mechanism 
 
The desired product (5) was obtained in 32% yield (determined on the 
crude by NMR with phenanthrene as internal reference standard). 
Using, the silylating agent trimethylsilyltrifluoromethanesulfonate, as 




was obtained in 70% yield, determined by NMR with phenanthrene as 
internal reference standard.  
Other combinations of bases, silylating agents and solvents were not 
successful, as summarised in table 3.3. 
In conclusion, this approach allows direct access to α-alkylated derivatives 
exploiting the formation of silyl-enol ether intermediate followed by 
alkylation through SN1 mechanism. Unfortunately, TMSOTf must be 
employed to obtain high yields, increasing considerably the production 
costs. As the latter is one of the most important issues in the development 




3.4. Reductive Amination 
The second approach identified during the retrosynthetic analysis of 
maropitant, was based on the reductive amination between (2S)-2-
benzhydryl-3-quinuclidinone and a benzylamine derivative bearing all the 
final substituents, namely 5-t-butyl-2-methoxybenzylamine. Unfortunately, 
this amine is commercially available only in milligram-to-gram amounts, 
with a prohibitive cost for industrial applications. We decided to undertake 
the preparation of this amine, planning a synthesis suitable for the 
manufacturing of large-scale amounts. 
We envisaged the preparation of 5-t-butyl-2-methoxybenzylamine through 
a Tscherniac-Einhorn reaction. This reaction was first reported by 
Tscherniac in 1901 and its potential further exploited by Einhorn in the 




classic Mannich reaction, in which the intermediate iminium ion is replaced 
by a more reactive acyliminium ion23.  
The driving force of this synthetic process is related to the formation of the 
superelectrophilic acyliminium ion (38, Scheme 3.17) from the starting 
material represented by a N-hydroxymethylamide (36, EWG = Electron 




Scheme 3.17: Formation of a superelectrophilic acyliminium ion  
 
The superelectrophilic acyliminium ion is able to react with aromatic 
substrate (39), ranging from activated ones to non-activated or even mildly 
deactivated arenes (Scheme 3.18) 
 
Scheme 3.18: Tscherniac-Einhorn reaction 
 
The α-amidoalkylated arene can be hydrolysed, by both acid or basic 





Synthetic applications of the Tscherniac-Einhorn reaction are extensively 
described in several articles and reviews24,25 where different substrate, 
reaction conditions and α-amidoalkylating agents are discussed. 
For our purpose, 5-t-butyl-2-methoxybenzylamine (47) was built using: 
- 4-t-butylanisole as the substrate;  
- N-hydroxymethyl-2-chloroacetamide (44) as the amidoalkylating 
agent.  
The amidoalkylating agent was synthesized in quantitative yield using 2-
chloroacetamide (42) and paraformaldehyde (43) following a reported 
procedure26 (Scheme 3.19). 
 
 
Scheme 3.19: N-hydroxymethyl-2-chloroacetamide preparation 
 
After the preparation of the amidoalkylating precursor, the Tscherniac-
Einhorn reaction was performed using a 9:1 mixture of acetic acid and 
sulphuric acid27 and 4-t-butyl anisole (45) leading to the clean formation of 
a mono-substituted product (46, Scheme 3.20), isolated in very good yield 







Scheme 3.20: Tscherniac-Einhorn reaction 
 
The amide group was hydrolysed using 37% aq. HCl in 2-propanol in order 
to obtain (after basification) the free amine (47, Scheme 3.21): 
 
 
Scheme 3.21: Amide hydrolysis in acid condition  
 
The desired 5-t-butyl-2-methoxybenzylamine (47) was obtained in a 2-step 
chromatography-free protocol, with an overall 89% yield from commercially 
available starting materials. 
5-t-Butyl-2-methoxybenzylamine can be employed for the reductive 
amination en route to maropitant. This specific step was performed by 
reacting (2S)-2-benzhydryl-3-quinuclidinone (7) and 5-t-butyl-2-
methoxybenzylamine (47), in dry DCM in presence of titanium(IV) 
tetraisopropoxide as drying agent and Pt/C as catalyst8, under dihydrogen 





Scheme 3.22: Alternative maropitant synthesis 
This approach to maropitant (1) avoids one combination of reductive 
amination/debenzylation and reduces the overall number of steps from 7 
to 5. Unfortunately, at this stage, the last step suffers from a low yield and 
moreover, chiral HPLC analysis showed the formation of diastereomers 
(Figure 3.5). This step clearly requires an extensive optimisation to improve 
either the yield and the stereoselectivity, for this alternative synthesis to be 
comparable in efficiency with the previously reported one. 
 







3.5. Current Maropitant synthesis 
An alternative and complementary strategy to the design of a radically 
alternative synthetic process is to analyse and revise the originally reported 
synthesis, with the aim to trace the main drawbacks and to develop 
innovative solutions to these problems.  
In the classical synthesis of maropitant7,10, the first step involves a cross 
aldol condensation of the commercial starting material 3-quinuclidinone 
hydrochloride and benzaldehyde, in presence of sodium hydroxide as 
base, leading to the (2Z)-2-benzylidene compound (4). The use of the 
cheapest base and the almost quantitative yield exclude any possible 
improvement in this step. 
The following conjugate addition of phenylmagnesium bromide on the Δα,β  
unsaturated system of compound 4 generates the racemic 2-benzhydryl-
3-quinuclidinone (5), but the yield of this step never exceeds a meagre 
50%, due to the concomitant formation of byproducts. The byproducts 
arise from the high reactivity of the Grignard reagent that can react with the 
carbonyl group, too. The addition of phenylmagnesium bromide to the 
ketone may occur on the unsaturated starting material 4 or even on the 
desired product 5, leading to the formation of misphenylated derivatives 
and eroding the yield.  
The literature reports several attempts to increase the efficiency of this 
step, varying the organometallic reagent and the experimental conditions.  
Patent US 356051013 reports the conjugate addition procedure using 
phenylmagnesium bromide, previously generated, and 2-Z-
benzylidenenone 4, leading to compound 5 in 52% yield. A different 




and copper iodide to give compound 5 in a poor 3% yield after 
chromatographic column and HPLC purification. 
During the PhD, we undertook a methodical investigation on the 
experimental conditions of this step. Fixing the reactants, (4 and PhMgBr), 
solvent, catalyst, concentrations, temperature and order and timing of 
addition were systematically varied. We were able to find a combination 
giving a strong improvement in the yield of this difficult step. 
In detail, we discovered that the combined use of copper(I) iodide as a 
catalyst and 2-methyltetrahydrofuran as the solvent (scheme 3.23) and 
with specific temperature and addition time, the yield of the second step 
was raised from 52% to 90% with an almost complete suppression of the 
well-known misphenylated byproducts. 
 
Scheme 3.23: Synthesis of the intermediate 5  
 
A patent covering IP issue related to the improved conditions for the 
selective conjugate addition was filed on the base of these results29.  
The synthesis of maropitant proceeds with the third step, involving a 
dynamic resolution of the racemic 5 with L-tartaric acid as the resolving 
agent, in ethanol with the addition of acetic acid. This procedure leads to 
the ketone with the correct configuration of benzhydryl moiety, i.e.: (2S)-2-
benzhydryl-3-quinuclidinone as the tartaric acid salt (6).  
Treatment of the salt with sodium hydrogen carbonate and extraction 




was obtained8 with virtually complete retention of the stereochemistry (S:R 
96:4) (7, Scheme 3.24). 
 
Scheme 3.24: Preparation of 2S-2-benzhydryl-3-quinuclidinone (7) 
 
Reductive amination of 7 with benzylamine was performed in a Parr reactor 
under hydrogen atmosphere (7 Atm) in the presence of 
titanium(IV)tetraisopropoxide as a drying agent, and Pt/C as catalyst8. The 
crude material was purified by crystallization leading to the desired product 
with an overall 61% yield for the two reactions (8, Scheme 3.25). Reductive 
amination by means of sodium triacetoxyborohydride (STAB) led to a 
complete erosion of the enantiomeric excess and to the formation of a large 
percentage of the unwanted stereoisomers. 
 
Scheme 3.25: Synthesis of the intermediate 8 
 
The benzylamine moiety was removed by a debenzylation procedure 
under hydrogen atmosphere in presence of Pd/C as catalyst leading to the 




treated with the commercial aldehyde (10) in a further reductive amination 
protocol relying on STAB as the reducing agent10 that generates 
maropitant free base (1, Scheme 3.26). 
 
 
Scheme 3.26: Synthesis of maropitant free base 
 
The preparation of the API is completed by treating the free base with citric 
acid, water and isopropyl ether31 leading to the final commercial form: 
maropitant citrate monohydrate (Scheme 3.27). 
 
 
Scheme 3.27: Preparation of maropitant citrate monohydrate 
 
The increase in the yield of the second step, almost doubled after the 
careful optimisation of the experimental conditions, led this process to be 
the most mature and convenient for the preparation of maropitant citrate 




Complete analytical characterisation of maropitant and all intermediates 
was achieved by different analytical methods (chiral HPLC, HPLC, UPLC-
MS and NMR). Additional parameters were checked (ICH solvent guide 
and presence of catalysts or other metals) in order to confirm the purity of 









Maropitant was the subject of the research activity of the first period of the 
PhD. The search of alternative and efficient syntheses was a complex task 
due to the variety of functional groups and stereocenters contained in this 
molecule. 
The introduction of the benzhydryl group on the quinuclidinone bicyclic 
skeleton was investigated using different reactions and led to the 
identification of two successful approaches, different failures and the 
formation of byproducts arising by competing reactions. Further efforts 
were devoted to reducing the number of steps of the total synthesis, 
achieved by overturning the reductive amination step and preparing the 
corresponding alternative starting material through a Tscherniac-Einhorn 
reaction. 
Among the two approaches leading to maropitant, one was selected in 
term of overall efficiency, stereochemical outcome and cost. This approach 


































3.7. Experimental section 
 
Solvents and reagents. Commercially available solvents and reagents 
were used without further purification. When needed, the reactions were 
performed under positive pressure of nitrogen or hydrogen. 
Spectra. NMR spectra were recorded using either 300 MHz on a Jeol 
Eclipse ECP300 or Bruker Avance Neo 400 MHz spectrometer. All NMR 
spectra were registered at 298 K. Chemical shifts (δ) are quoted to parts 
per million referenced to the residual solvent peak. The multiplicity of each 
signals is designated using the following abbreviations: s, singlet; d, 
doublet; t, triplet, q, quartet; quint, quintet; sext, sextet; hept, heptet; m, 
multiplet, br s, broad singolet; br m, broad multiplet. Coupling constants (J) 
are reported in Hertz (Hz).  
The reactions and mass analysis were monitored by UPLC-MS analysis, 
typically using a column ACQUITY UPLC® BEH C18 1.7 μm, 2.1x50 mm, 









































In a round 50 mL bottomed flask, equipped with magnetic stirrer, 2-
chloroacetamide (10 g, 106.94 mmol, 1.00 eq), paraformaldehyde (3.44 g, 
114.42 mmol, 1.07 eq) and potassium carbonate (4.88 g, 37.43 mmol, 0.35 
eq) were dissolved in 10 mL of water. The resulting mixture was heated to 
70 °C for 1 h then cooled to room temperature. The obtained white solid 
was filtered off, washed with cooled water and dried in vacuum at 40°C26. 
1H (300 MHz, D2O): δ 5.44 (s, 2H), 4.24 (s, 2H) ppm 











In a 25 mL round bottomed flask, equipped with magnetic stirrer, N-
hydroxymethyl-2-chloroacetamide (44, 0.300 g, 2.43 mmol, 1.00 eq) was 
dissolved in acetic acid (2.7 mL). 4-t-Butylanisole (0.425 mL, 2.43 mmol, 
1.00 eq) was added followed by conc. sulphuric acid (0.3 mL). The 
obtained solution was stirred until completion assessed by TLC 
(DCM/MeOH 9:1). Then, water (10 mL) was added followed by a saturated 
solution of sodium bicarbonate until pH 8. The mixture was extracted with 
DCM three times (3 x 10 mL) and the organic extracts were pooled and 
washed with brine (20 mL), dried with sodium sulphate, filtered and 
concentrated under vacuum to give a white solid (92%)27. 
1H (300 MHz, CDCl3): δ 7.32 (d, J = 2.7 Hz, 2H), 6.87 – 6.81 (m, 1H), 4.49 
(d, J = 5.8 Hz, 2H), 4.02 (s, 2H), 3.86 (s, 3H), 1.30 (s, 9H). 
13C-APT (75 MHz, CDCl3): δ 165.5, 155.7, 143.6, 127.2, 125.9, 124.7, 









In a 25 mL round bottomed flask, equipped with magnetic stirrer, 
compound 46 (0.458 g, 1.70 mmol, 1.00 eq) was added followed by 2-
propanol (5 mL). HCl 37% (2.8 mL) was added and the resulting mixture 
was heated to reflux until complete conversion of the starting material.  The 
mixture was diluted with water and extracted with DCM (3 x 10 mL). The 
organic extracts were concentrated and the obtained residue was purified 
by column chromatography using DCM/MeOH 9:1 as mixture of solvents. 
1H (300 MHz, CDCl3): δ 7.29-7.26 (m, 2H), 6.78 (d, J = 8.3 Hz, 1H), 3.95 
(bs, 2H), 3.80 (s, 3H), 3.37-3.35 (m, 1 H), 1.27 (s, 9H) ppm. 
13C-APT (75 MHz, CDCl3): δ 155.5, 143.5, 127.4, 126.3, 124.4, 110.0, 







benzhydrylquinuclidin-3-amine (Maropitant free base, 1) 
 
 
(2S)-2-Benzhydryl-3-quinuclidinone 7 (1.51 g, 5.17 mmol, 1.00 eq) was 
dissolved in anhydrous DCM (30 mL) and transferred to a Parr reactor 
under nitrogen atmosphere. 5-t-Butyl-2-methoxybenzylamine (10, 1.04 
mL, 5.17 mmol, 1.00 eq) was added followed by titanium (IV) 
tetraisopropoxide (4.0 mL, 12.93 mmol, 2.50 eq). 5% Pt/C (0.192 g, 0.985 
mmol, 0.19 eq) was added and the mixture was stirred at room temperature 
for 3 hours, then pressurized to 7 atm with hydrogen. The mixture was held 
in stirring for 12 hours at room temperature and monitored until conclusion. 
The mixture was filtered through a Celite™ pad under vacuum and the 
filtrate was washed with a saturated sodium carbonate solution (30 mL) 
and filtered through a Celite™ pad under vacuum to remove the titanium 
salts. The organic phase was washed with brine (20 mL), dried on sodium 
sulphate, filtered and concentrated under vacuum. The residue was 
purified by silica gel column chromatography using DCM/MeOH 95:5 as 









In a four necked round bottomed flask, equipped with a mechanical stirrer, 
3-quinuclidinone hydrochloride (600.0 g, 3.71 mol, 1.0 eq) and ethanol 
(850 mL) were added under nitrogen atmosphere. Then, NaOH 50% (260 
mL, 4.94 mol, 1.33 eq) was added dropwise over 15 minutes and the 
reaction mixture was warmed to 30 °C. A solution of benzaldehyde (379 
mL, 3.71 mol, 1.0 eq) in ethanol (394 mL) was added and the resulting 
mixture was heated to 50 °C until completion (UPLC analysis). Water (780 
mL) was added to the reaction at 50 °C and stirring was continued for 1 
hour, then cooled to room temperature over 2 hours. After 1 additional 
hour, the yellow solid was collected by filtration under vacuum and washed 
with ethanol (910 mL) and water (600 mL). The solid was dried in vacuum 
at 50 °C for 1 day (yield 95%)9.  
1H (400 MHz, CDCl3): δ 8.03 (dd, J1= 10.6, J2= 2.84 Hz, 2H), 7.38-7.32 (m, 
3H), 7.02 (s, 1H), 3.19-3.09 (m, 2H), 3.02-2.96 (m, 2H), 2.61 (q, J=2.9, 1H), 
2.00 (td, J1= 7.6, J2= 2.8 Hz, 4H) ppm. 
13C-APT (101MHz, CDCl3): δ 206.4, 144.7, 134.0, 132.2, 129.6, 128.4, 
125.2, 47.5, 40.3, 25.9 ppm. 








In a four necked 10 L round bottomed flask, equipped with a mechanical 
stirrer, a dropping funnel and a thermometer, MeTHF (3630 mL) and 
PhMgBr 45% in MeTHF 2.9M (645.0 mL, 1.86 mol, 1.20 eq) were added. 
The resulting solution was cooled to 0 °C and copper iodide (17.68 g, 0.093 
mol, 0.06 eq) was added. The mixture was stirred at 0 – 2 °C for 10 
minutes, under nitrogen atmosphere, then (2Z)-2-benzylidenequinuclidin-
3-one (4, 330.0 g, 1.55 mol, 1.0 eq) was added in portions. The mixture 
was stirred until conclusion (30 minutes). The resulting solution was 
allowed to room temperature then slowly added over a solution of NH4Cl 
(20% acq. solution, 238.38 g, 4.46 mol) in water (1188 mL) and the 
biphasic mixture was separated. The organic phase was washed with 
NH4OH twice (2 x 1320 mL) followed by water (4 x 1320 mL) and brine 
(1320 mL). The solvent was removed in vacuum and a white solid was 
obtained. Ethanol (1320 mL) was added and heated until complete 
dissolution then cooled at room temperature over 16h. The resulting solid 
was filtered under vacuum, washed with ethanol (660 mL) and dried in 
vacuum stove for 16 h (yield 90%, purity > 99%)29. UPLC-MS calculated 
for C14H17NO: 291.38, found: 292.42. 
NMR: 1H (400 MHz, CDCl3): δ 7.43-7.15 (m, 10H), 4.58 (d, J= 7.95 Hz, 
1H), 4.02(d J= 7.95, 1H), 3.12 (t, J= 7.65 Hz, 2H), 2.68-2.42 (m, 3H), 2.08-




13C-APT (101 MHz, CDCl3): δ 199.3, 128.5, 128.4, 126.6, 126.5, 72.6, 





(2S)-2-Benzhydryl-3-quinuclidinone L-tartaric salt (6) 
 
 
In a four necked 10 L round bottomed flask, equipped with mechanical 
stirrer and thermometer, rac-2-benzhydryl-3-quinuclidinone 5 (740.0 g, 
2.54 mol, 1.00 eq) was dissolved in denatured ethanol (5% methanol, 5% 
2-propanol) (7400 mL) with acetic acid (145 mL, 2.54 mol, 1.00 eq). L-
tartaric acid (381.15 g, 2.54 mol, 1.00 eq) was added and the resulting 
mixture was heated to reflux for 12 h then cooled to room temperature. The 
white solid was collected by filtration under vacuum and dried under 
vacuum stove at 40 °C (yield 88%, ee 96%)8.  
1H (400 MHz, DMSO-d6): δ 7.42 – 7.35 (m, 4H), 7.21-7.18 (m, 4H), 7.11 – 
7.06 (m, 2H), 4.35 – 4.28 (m, 4H), 3.04 – 2.80 (m, 3H), 2.52 – 2.45 (m, 2H), 
2.23 – 2.20 (m, 2H), 2.03 – 1.85 (m, 2H) ppm. 
13C (101 MHz, DMSO-d6): δ 219.2, 173.6, 144.2, 128.7, 128.5, 126.2, 72.6, 
70.6, 50.9, 48.6, 41.0, 25.9, 25.8 ppm 










In a flask equipped with magnetic stirring bar and pH-meter, (2S)-2-
benzhydryl-3-quinuclidinone L-tartaric salt 6 (500.0 g, 1.13 mol, 1.00 eq) 
was suspended in toluene (5000 mL) and cooled with an ice-water bath. 
NaHCO3 saturated solution (3600 mL) was added dropwise maintaining 
the temperature under 25 °C. The clear biphasic solution was stirred for 30 
minutes at 25 °C then separated. The organic phase was washed with 
water (750 mL) and concentrated under vacuum and dried in vacuum stove 
for 16h to provide the desired product in quantitative yield8. Chiral HPLC 









(2S)-2-Benzhydryl-3-quinuclidinone 7 (61.0 g, 0.209 mol, 1.0 eq) was 
dissolved in anhydrous THF (700 mL) and transferred to a Parr reactor 
under nitrogen atmosphere. Then, benzylamine (25.2 mL, 0.230 mol, 1.1 
eq) and titanium (IV) tetraisopropoxide (93 mL, 0.314 mol, 1.50 eq) were 
added and the mixture was stirred at room temperature for 3 hours. 5% 
Pt/C (7.66 g, 0.039 mol, 0.19 eq) was added and the Parr reactor was 
pressurized to 7 atmospheres with hydrogen. The mixture was held in 
stirring for 12 hours at room temperature. The Parr reactor is vented and 
hydrochloric acid 12.4 % (190 mL H2O + 95 mL HCl 37%, 285 mL) was 
added and the mixture was kept in stirring for 1 hour then filtered through 
a Celite™ pad under vacuum. The filter cake was washed with toluene 
(340 mL). The biphasic system was separated and the aqueous phase was 
transferred into flask. Toluene (340 mL) was added to the acid aqueous 
phase and NaOH was added until pH was 13. The mixture was filtered 
through a Celite™ pad under vacuum to remove the titanium salts. The 
cake was washed with toluene (2x100 mL) and the layers were separated. 
The organics were concentrated under vacuum leading to a solid. The 
latter was dissolved in freshly toluene (150 mL) and n-hexane (300 mL) 




precipitate was filtered and washed with toluene/n-hexane 1/6 (300 mL) 
and dried under vacuum stove at 40 °C (yield 61% over two steps).8 
 
1H (400 MHz, DMSO-d6): δ 7.61 – 7.38 (m, 2H), 7.37 – 7.18 (m, 4H), 7.17 
– 7.06 (m, 4H), 7.01 (t, J = 7.3 Hz, 1H), 6.74 – 6.39 (m, 2H), 4.40 (d, J = 
12.2 Hz, 1H), 3.95 – 3.68 (m, 1H), 3.49 (d, J = 13.4 Hz, 1H), 3.09 (dd, J = 
24.1, 12.4 Hz, 2H), 2.80 – 2.52 (m, 3H), 2.45 – 2.19 (m, 1H), 2.01 – 1.86 
(m, 1H), 1.81 (d, J = 10.6 Hz, 1H), 1.66 – 1.34 (m, 3H), 1.15 (q, J = 10.2 
Hz, 1H) ppm. 
13C NMR (101 MHz, DMSO-d6) δ 140.6, 129.4, 128.4, 128.3, 128.1, 128.0, 
126.8, 126.5, 60.8, 54.3, 51.7, 49.3, 41.9, 25.3, 24.7 ppm. 








(2S,3S)-2-Benzhydryl-3-benzhydrylquinuclidine 8 (76.0 g, 0.199 mol, 1.0 
eq) was dissolved in methanol (760 mL). The solution was transferred into 
a Parr reactor. Pd/C 10% (50% H2O) (7.80 g, 0.073 mol, 0.37 eq) was 
added and hydrogen was charged (7 atm) and heated for 6h at 100 °C. 
The catalyst was removed by filtration under vacuum on a Celite™ pad, 
and the filtrate was treated with NaOH 2M (760 mL) then separated. The 
organic phase was concentrated under vacuum giving a white solid (yield 
95%)12.  
1H (400 MHz, CDCl3): δ 7.48 - 7.09 (m, 10H), 4.59 (d, J= 12.24 Hz, 1H), 
3.69 (dt, J1= 12.2 Hz, J2 = 7.6 Hz, 1H), 3.31 - 3.20 (m, 2H), 2.85 (t, J = 7.95 
Hz, 2H), 2.68 (t, J = 11.9 Hz, 1H), 1.98 – 1.87 (m, 1H), 1.81 – 1.80 (m, 1H), 
1.69 – 1.60 (m, 2H), 1.36 – 1.25 (m, 1H), 1.08 (s, 2H) ppm. 
13C-APT (101 MHz, CDCl3): δ 145.2, 144.1, 129.2, 128.5, 127.9, 127.7, 
126.6, 126.1, 62.4, 49.8, 49.7, 49.4, 41.5, 29.5, 26.6, 19.9 ppm 










To a solution of 5-t-butyl-2-methoxybenzaldehyde 10 (59.17 g, 0.308 mol, 
1.00 eq) and (2S,3S)-2-benzhydryl-3-aminoquinuclidine 9 (108.0 g, 0.369 
mol, 1.20 eq) in methylene chloride (1100 mL), sodium 
triacetoxyborohydride (97.84 g, 0.462 mol, 1.50 eq) was added in small 
portions. The mixture was stirred at room temperature for 2 h then 
transferred into flask and neutralized using NaHCO3 until pH was 8. The 
biphasic system was separated and the organic phase was dried over 
sodium sulphate, filtered and concentrated under vacuum to give a white 
solid (yield 80%)10.  
1H (400 MHz, CDCl3): δ 7,40 - 7,37 (m, 2H), 7,31 - 7,27 (m, 2H), 7.25 – 
7.17 (m, 6H), 7.13 – 7.08 (m, 1H), 6.97 (d, J = 2.6 Hz, 1H), 6.70 (d, J = 8.5 
Hz, 1H), 4.57 (d, J = 12.1 Hz, 1H), 3.79 – 3.62 (m, 2H), 3.58 (s, 3H), 3.31 
– 3.13 (m, 2H), 2.98 (dd, J1 = 7.9 Hz, J2 = 4.2 Hz, 1H), 2.85 – 2.80 (m, 2H), 
2.68 – 2.61 (m, 1H), 2.17 – 2.13 (m, 1H), 2.03 – 1.96 (m, 1H), 1.75 – 1.67 




13C-APT (101 MHz, CDCl3): δ 155.3, 145.6, 143.4, 142.6, 128.9, 128.3, 
127.6, 127.6, 127.0, 126.3, 125.8, 124.3, 109.5, 61.9, 55.3, 55.1, 49.3, 
31.6, 25.1 ppm 





















To a white slurry of maropitant free base 1 (90.0 g, 0.192 mol, 1.0 eq) in 
isopropyl ether (900 mL), anhydrous citric acid (36.89 g, 0.192 mol, 1.0 eq) 
was added at room temperature. Water (270 mL) was added and the 
resulting mixture was held in stirring for 18 hours. The desired product was 
collected by filtration under vacuum31 (yield 96%). 
 
1H (400 MHz, CD3OD): δ 7,45 - 7,42 (m, 4H), 7,35 - 7,31 (m, 4H), 7.26 (t, 
J = 7.12 Hz, 2H), 7.22 (dd, J1 = 8.6 Hz, J2 = 2.5 Hz, 1H), 6.93 (d, J = 2.5 
Hz, 1H), 6.72 (d, J = 8.6 Hz, 1H), 4.73 (dd, J1 = 12.5 Hz, J2 = 7.3 Hz, 1H), 
4.68 (d, J = 12.4 Hz, 1H), 3.72 (m, 1H), 3.54 (d, J = 12.2 Hz, 1H), 3.5 (s, 
3H), 3.38 – 3.24 (m, 3H), 3.22 (d, J = 12.2 Hz, 1H), 3.10 (bt, J = 11.6 Hz, 
1H), 2.80 (d, J = 15.4 Hz, 2H), 2.73 (d, J = 15.4 Hz, 2H), 2.47 (m, 1H), 2.30 
(m, 1H), 2.11 – 1.88 (m, 2H), 1.81 (m, 1H), 1.26 (s, 9H) ppm 
13C (101 MHz, CD3OD): δ 177.90, 173.6, 155.40, 142.6, 140.1, 140.0, 
129.7, 129.3, 128.0, 127.6, 127.4, 127.0, 126.8, 125.7, 125.1, 109.6, 72.6, 
63.2, 54.7, 52.8, 49.0, 47.1, 46.9, 43.5, 42.3, 33.4, 30.6, 23.8, 20.8, 16.7 
ppm 












1. Lesman, S. P.; Boucher, J. F.; Grover, G. S.; Cox, S. R.; Bidgood, T. 
L. The Pharmacokinetics of Maropitant Citrate Dosed Orally to Dogs 
at 2 mg/Kg and 8 mg/Kg Once Daily for 14 Days Consecutive Days. J. 
Vet. Pharmacol. Ther. 2013, 36 (5), 462–470. 
https://doi.org/10.1111/jvp.12027. 
2. de la Puente-Redondo, V. A.; Tilt, N.; Rowan, T. G.; Clemence, R. G. 
Efficacy of Maropitant for Treatment and Prevention of Emesis Caused 
by Intravenous Infusion of Cisplatin in Dogs. Am. J. Vet. Res. 2007, 68 
(1), 48–56. https://doi.org/10.2460/ajvr.68.1.48. 
3. Benchaoui, H. A.; Siedek, E. M.; De La Puente-Redondo, V. A.; Tilt, 
N.; Rowan, T. G.; Clemence, R. G. Efficacy of Maropitant for 
Preventing Vomiting Associated with Motion Sickness in Dogs. Vet. 
Rec. 2007, 161 (13), 444–447. https://doi.org/10.1136/vr.161.13.444. 
4. Hickman, M. A.; Cox, S. R.; Mahabir, S.; Miskell, C.; Lin, J.; Bunger, 
A.; McCALL, R. B. Safety, Pharmacokinetics and Use of the Novel NK-
1 Receptor Antagonist Maropitant (Cerenia TM ) for the Prevention of 
Emesis and Motion Sickness in Cats. J. Vet. Pharmacol. Ther. 2008, 
31 (3), 220–229. https://doi.org/10.1111/j.1365-2885.2008.00952.x. 
5. Tsukamoto, A.; Ohgoda, M.; Haruki, N.; Hori, M.; Inomata, T. The Anti-
Inflammatory Action of Maropitant in a Mouse Model of Acute 
Pancreatitis. J. Vet. Med. Sci. 2018, 80 (3), 492–498. 
https://doi.org/10.1292/jvms.17-0483. 





Methoxybenzyl)-Amine Citrate as Nk-1 Receptor Antagonists. 
WO0073303 (A1), December 7, 2000. 
7. Basford, P. A.; Post, R. J.; Smith, J. D.; Taber, G. P. Process for 
Preparation of 1-(2S,3S)-2-Benzhydryl-N-(5-t-Butyl-2-Methoxybenzyl) 
Quinuclidin-3-Amine. WO2005075473 (A1), August 18, 2005. 
8. Nugent, T. C.; Seemayer, R. An Efficient Enantiopure Synthesis of a 
Pivotal Precursor to Substance P Antagonists. Org. Process Res. Dev. 
2006, 10 (1), 142–148. https://doi.org/10.1021/op050213e. 
9. Chandramouli, S. V.; Ayers, T. A.; Wu, X.-D.; Tran, L. T.; Peers, J. H.; 
Disanto, R.; Roberts, F.; Kumar, N.; Jiang, Y.; Choy, N.; et al. Scale-
Up of an Enantioselective Overman Rearrangement for an Asymmetric 
Synthesis of a Glycine Transporter 1 Inhibitor. Org. Process Res. Dev. 
2012, 16 (3), 484–494. https://doi.org/10.1021/op200378r. 
10. Ito, F.; Kondo, H.; Nakane, M.; Lowe, I. J. A.; Rosen, T. J.; Shimada, 
K. Quinuclidine Derivatives. US6222038 (B1), April 24, 2001. 
11. McCarson, K. E. L703606. In xPharm: The Comprehensive 
Pharmacology Reference; Elsevier, 2007; pp 1–4. 
https://doi.org/10.1016/B978-008055232-3.62000-8. 
12. Warawa, E. J.; Mueller, N. J.; Fleming, J. S. Quinuclidine Chemistry. 
4. Diuretic Properties of Cis-3-Amino-2-Benzhydrylquinuclidine. J. 
Med. Chem. 1975, 18 (6), 587–593. 
https://doi.org/10.1021/jm00240a013. 
13. Warawa, E. J. 2-Benzhydrylquinuclidines. US3560510 (A), February 2, 
1971. 
14. Aggarwal, V. K.; Staubitz, A. C.; Owen, M. Optimization of the 




Process Res. Dev. 2006, 10 (1), 64–69. 
https://doi.org/10.1021/op058013q. 
15. Progress in Organic Chemistry; Cook, J., Carruthers, W., Eds.; 
Springer US: Boston, MA, 1968. https://doi.org/10.1007/978-1-4899-
7315-3. 
16. Millard, B. J.; Stevens, T. S. 630. Electrophilic Rearrangements: 
Stereochemistry and Allylic Transformations. J. Chem. Soc. Resumed 
1963, No. 0, 3397–3403. https://doi.org/10.1039/JR9630003397. 
17. Hoffmann, R. W. Stereochemistry of [2,3]Sigmatropic 
Rearrangements. Angew. Chem. Int. Ed. Engl. 1979, 18 (8), 563–572. 
https://doi.org/10.1002/anie.197905633. 
18. Ollis, W. D.; Rey, M.; Sutherland, I. O. Base Catalysed 
Rearrangements Involving Ylide Intermediates. Part 15. The 
Mechanism of the Stevens [1,2] Rearrangement. J. Chem. Soc. Perkin 
1 1983, No. 0, 1009–1027. https://doi.org/10.1039/P19830001009. 
19. Brieden, W. D. Method for the Preparation of Optically Active 3-
Hydroxyquinuclidine. EP0785198 (A1), July 23, 1997. 
20. Taniguchi, Y.; Inanaga, J.; Yamaguchi, M. Use of 1,8-
Diazabicyclo[5.4.0]Undec-7-Ene in Preparation of Trimethylsilyl Enol 
Ethers and Trimethylsilylacetylenes. Bull. Chem. Soc. Jpn. 1981, 54 
(10), 3229–3230. https://doi.org/10.1246/bcsj.54.3229. 
21. Downey, C. W.; Johnson, M. W.; Tracy, K. J. One-Pot Enol Silane 
Formation-Mukaiyama Aldol-Type Addition to Dimethyl Acetals 
Mediated by TMSOTf. J. Org. Chem. 2008, 73 (8), 3299–3302. 
https://doi.org/10.1021/jo8001084. 
22. Tscherniac-Einhorn Reaction: (Tscherniac-Einhorn Amidomethylation, 




Name Reactions and Reagents; John Wiley & Sons, Inc.: Hoboken, 
NJ, USA, 2010. https://doi.org/10.1002/9780470638859.conrr629. 
23. Olah, G. A.; Wang, Q.; Sandford, G.; Oxyzoglou, A. B.; Surya Prakash, 
G. K. Superelectrophilic Tscherniac Amidomethylation of Aromatics 
with N -Hydroxymethylphthalimide in Trifluoromethanesulfonic Acid. 
Synthesis 1993, 1993 (11), 1077–1079. https://doi.org/10.1055/s-
1993-26001. 
24. Zaugg, H. E. α-Amidoalkylation at Carbon: Recent Advances - Part I. 
Synthesis 1984, 1984 (02), 85–110. https://doi.org/10.1055/s-1984-
30740. 
25. Zaugg, H. E. α-Amidoalkylation at Carbon: Recent Advances - Part II. 
Synthesis 1984, 1984 (03), 181–212. https://doi.org/10.1055/s-1984-
30772. 
26. Murata, H. Method for Synthesizing N-Methylol Compound. 
JP2003171357 (A), June 20, 2003. 
27. Tamura, K.; Kato, Y.; Ishikawa, A.; Kato, Y.; Himori, M.; Yoshida, M.; 
Takashima, Y.; Suzuki, T.; Kawabe, Y.; Cynshi, O.; et al. Design and 
Synthesis of 4,6-Di- Tert -Butyl-2,3-Dihydro-5-Benzofuranols as a 
Novel Series of Antiatherogenic Antioxidants. J. Med. Chem. 2003, 46 
(14), 3083–3093. https://doi.org/10.1021/jm030062a. 
28. Boudhar, A.; Ng, X. W.; Loh, C. Y.; Chia, W. N.; Tan, Z. M.; Nosten, 
F.; Dymock, B. W.; Tan, K. S. W. Overcoming Chloroquine Resistance 
in Malaria: Design, Synthesis and Structure–Activity Relationships of 





29. Donnola, M.; Mossotti, M.; Barbero, M.; Roletto, J.; Paissoni, P. 
Process for the Synthesis of 2-Benzhydryl-3 Quinuclidinone. 
WO2019086434 (A1), May 9, 2019. 
30. Swain, C. J.; Seward, E. M.; MacIntyre, D. E.; Merchant, K. J.; Owen, 
S. N.; Owens, A. P.; Sabin, V.; Teall, M.; VanNiel, M. B.; Williams, B. 
J.; et al. Identification of a Series of 3-(Benzyloxy)-l-
Azabicyclo[2.2.2]Octane, Human NK-1 Antagonists.  
31. Castaldi, M. J.; Quallich, G. J.; Wint, L. T. Polymorphs of a Crystalline 
Azabicyclo (2,2,2) Octan-3-Amine Citrate and Their Pharmaceutical 













































Vanillin (1, 4-hydroxy-3-methoxybenzaldehyde) is one of the most 
common flavouring agent, widely used in foods, beverages, food-
supplements, perfumes and pharmaceuticals1. This aromatic aldehyde is 
extracted from the berries of orchids of the genus Vanilla. Due to the high 
extraction costs and the low yield of extraction, synthetic vanillin is 
available to satisfy the worldwide request. More recently, a new synthetic 
derivative of vanillin was produced, i.e.: ethyl-vanillin 2 (bourbonal, 3-
ethoxy-4-hydroxybenzaldeyde), is gaining space in the flavouring industry, 
due to its stronger and persistent aroma (Figure 4.1). 
 
 
Figure 4.1: Structures of Vanillin and Ethylvanillin 
 
As mentioned above, different synthetic strategies have been developed 
for the production of synthetic vanillin. Recent examples include the work 
of the research group of Liu et al2 involving a method based on the iron-
catalized oxidative C-C bond cleavage of allylarenes to the corresponding 
arylaldehyde. Following this procedure, vanillin is produced in 84% yield. 
An alternative method was reported by Taber at al3 in which vanillin was 




followed by substitution of the bromine atom with a methoxide group in the 
presence of copper(I)bromide as catalyst, in 74% yield (Scheme 4.1).  
 
 
Scheme 4.1: Reported synthesis of vanillin 
 
Both the two cases reported the use of a chromatographic separation in 
order to obtain the pure vanillin. The latter technology cannot be applied in 
industries due to the high associated costs. For these reasons, alternative 
production processes were developed based on the biotechnological 
transformations, employing different microorganisms and starting 
materials. Kaur – Chakraborty4, Chattopadhyay5, Banerjee – 
Chattopadhyay1 and Gallage – Møller6, reported different and alternative 
methods for the biotechnological production of vanillin using different 
starting material like ferulic acid, eugenol, isoeugenol and lignin. These 
transformations can be made using several microorganisms as bacteria 
(S. sannanensis MTCC 6637), fungi and genetic modified organisms. The 
aims of these researches were focused on the identification of large scale 
inexpensive starting materials (agro-residues) suitable for the production 
of vanillin. FDA approved the use of vanillin in 1977 in foods and 
beverages. This compound shows a robust safety profile and several 
studies even claimed the potential anti-bacteria7, anti-oxidant8 and anti-
mutagens9,10 activities. Nevertheless, Chen and co. workers11, showed 




inhibitor of the CYP1A2. These data revealed that the drug interaction 
between vanillin and CYP2E1/1A2 can be possible. This result suggests 
that use of this additive in foods should be accompanied with more 
attention. Moreover, these results can suggest that vanillin could interact 
with endogenous molecules even if no data are available to support this 
theory. 
Vanillin is widely used in foods, especially in cooked products (biscuits, 
cakes), increasing the possibility of the vanillin to take a role during 
reactions involving functional groups presents in other ingredients, as for 
example eggs and flour. To our knowledge, the literature does not report 
any evidence of the formation of vanillin-related by-products during the use 
of this flavouring compound.  
This work complements and completes an investigation started in a 
previous PhD work12. During the investigation of the reactions of vanillin 
with amines, initially addressed to the isolation of quinomethides, we 
registered a surprising and efficient formation of coloured products with 
secondary amines. Treatment of vanillin (1) with excess morpholine (2a) in 
alcoholic solution at room temperature gave an initially complex mixture of 
coloured compounds as evidenced by TLC analysis, evolving overnight 
towards the precipitation of a brick red crystalline compound. Isolation of 
the precipitate and analysis by NMR and HRMS led to the identification of 
this product as 2,5-dimorpholino-1,4-benzoquinone (3a) (Scheme 4.2). 
Comparison of the product with a sample prepared by an independent 






Scheme 4.2: Reaction of vanillin with secondary amines in aerobic 
conditions 
 
Startled by this initial result, we undertook a systematic investigation of this 
strange reaction by exploring its versatility towards different amines. 
Different secondary aliphatic amines (2a-e, Figure 4.2) were found to react 
in the same way, providing good to excellent yields of the corresponding 
substituted 2,5-diamino-1,4-benzoquinones (3a-e). Proline (2f) reacts 
leading the corresponding quinone 3f, in the presence of Na2CO3. This is 
especially noteworthy as this proteinogenic amino acid may be present in 
the free form in some foods. Secondary aromatic amines failed to react 
significantly while aliphatic and aromatic primary amines yielded variable 






Figure 4.2: Disubstituted 1,4-benzoquinone with relative yields. 
 
We examined the experimental conditions in order to gain additional 
information on the possible mechanism. The reactions run at room 
temperature for 24h yielded 2,5-diamino-1,4-benzoquinones as 
summarised in Scheme 1. Heating or refluxing speeded up the formation 
of the 2,5-diamino-1,4-benzoquinones. Alcoholic solvents like methanol 
and ethanol were the best solvents, while either apolar or more polar 
solvents led to incomplete reactions and/or complex mixtures, mainly 
ascribed to the limited solubility of the reagents. The reaction atmosphere 
was the subject of particular attention. The reactions proceeded sluggishly 
under nitrogen atmosphere but restoring the aerobic condition the 
reactions reached complete conversion, suggesting a direct role of oxygen 
in the reaction mechanism. Atom mapping allowed to trace back the 
quinone skeleton to the aromatic ring of vanillin, with the evident excision 
of the carbon atom of the aldehyde group. Analysis of the residual mother 




identified by NMR as N-formylmorpholine (4a), later confirmed by 
comparison with the commercially available compound by GC.  An 
analogous reaction between vanillin and dimethylamine (2e) clearly 
showed by GC analysis the formation of N,N-dimethylformamide (DMF), 
identifying the fate of the missing carbon atom.  
The experimental evidences arising by this preliminary investigation led us 
to sketch a possible mechanism for this reaction (Scheme 4.3). The 
transformation of vanillin to 2,5-diamino-1,4-benzoquinones starts with a 
dehydrative condensation of the arylaldehyde with the secondary amine 
(morpholine 2a in Scheme 3.3) to give an intermediate iminium ion 5a. 
Deprotonation gives the morpholinoquinomethide 6a. Structural analogues 
of 6a were described as intermediates in cycloadditions14 ad sometimes 
isolated15. Aerobic oxidation of the enamine portion16 of the 
dialkylaminoquinomethide is known to take place on similar compounds 
through a SET mechanism17 generating the unstable dioxetane 7a. The 
four-membered ring promptly fragments18 to 2-methoxy-1,4-benzoquinone 
8a and to the identified byproduct N-formylmorpholine 4a. Conversion of 
the quinone 8a to the final 2,5-dimorpholino-1,4-benzoquinone 3a may 
occur through two alternative and converging pathways, involving standard 
quinone chemistry19: i) the secondary amine undergoes to a conjugate 
addition to giving 2-amino-5-methoxyhydroquinone 9a, then oxidised (by 
oxygen or by the quinones present in the reaction mixture) to the 
corresponding 1,4-benzoquinone 10a; finally giving 3a by an ipso-
substitution of the -OCH3 group operating through a combined addition-
elimination19; ii) preliminary nucleophilic ipso-substitution of the -OCH3 
group by the secondary amine leading to an intermediate 2-amino-1,4-




to give the intermediate 2,5-diaminohydroquinone 12a, finally oxidised (by 
oxygen or by the quinones present in the reaction mixture) to the stable 
end-product 3a. 
 
Scheme 4.3: Proposed mechanism for the formation of disubstituted 1,4-
benzoquinones 
 
Two additional experiments endorse the proposed mechanism. Reaction 
of the commercially available quinone 8a with excess morpholine in 
ethanol at room temperature in aerobic conditions overnight gave good 
yields of 3a, confirming its involvement as intermediate in the reaction 
pathway. Moreover, “bourbonal” gave as expected the same 2,5-diamino-
1,4-benzoquinones on reaction with amines 2a-f. Slightly longer reaction 
times were needed to reach complete conversion. Due to the efficiency of 




conditions and with good to excellent yields, the possibility of this reaction 
to take place during cooking processes in the hot aerobic environment of 
baking ovens may raise some safety concerns. 
Vanillin is commonly added to foods before baking or sprayed as an 
ethanolic solution after cooking on their surface, with the aim to aromatise 
the baked product. In addition, free proline can be present in different 
ingredients (milk powders, flours), as well as other secondary amines 
released during the Maillard’s reaction. The formation of 2,5-diamino-1,4-
benzoquinones (namely 3f) is then conceivable in products enriched by 
free amino acids (e.g.: baked enriched foods or food for medical uses).  
For this reason, we undertaken preliminary toxicity tests (in collaboration 
with Prof. F. Condorelli, Dipartimento di Scienze del Farmaco) to evaluate 
the potential biological effect of 2,5-diamino-1,4-benzoquinone. No 
literature data are available for this family of compounds except for the 2,5-
diaziridino analogues, where cytotoxicity and mutagenicity is well 
documented20 but obviously related to the presence of the strained three-
membered heterocyclic rings rather than to the benzoquinone. These tests 
show that 2,5-diamino-1,4-benzoquinones are not toxic even at 100 µM 
concentrations. In detail, MTT-based assays were exploited in vitro to test 
the effect of our compounds on viability of renal (HEK293T) and 
hepatocytic (HepG2) human cell lines, pointing out to a negligible toxicity 
at concentrations compatible with alimentary exposure. Thus, although 
more detailed investigation is needed, our observations exclude at this 
stage undesired biological activities for these compounds. 
Colour is a fundamental attractive sensorial feature of baked products, and 
the Maillard reactions are well known to contribute to the development of 




to brilliant dark red tones shown by the 2,5-diamino-1,4-benzoquinones 
could be a contributor to the overall colour perceived in bakery products. 
Furthermore, the colouring properties of these compounds can be 
estimated to select novel potential candidates as “new” colorant additives 






In conclusion, in this work we report the observation of an unprecedented 
reaction of vanillin with secondary alkylamines in aerobic conditions, 
generating 2,5-diamino-1,4-benzoquinones. This complex reaction 
appears to involve several steps and intermediates, as typified by the 
proposed reaction mechanism, sketched following the results of suitably 
designed experiments and on the base of literature records in quinone 
chemistry. The relevance of this novel transformation resides in the 
possibility of this reaction to happen more frequently than considered until 
now, due to the widespread use of vanillin (and its derivatives as 
ethylvanillin) and the occurrence of secondary amines, either biogenic or 
thermally/chemically generated during food processing. These outcomes 
give new insights on the potential red-orange colour tone development in 
baked foods, complementary to the browning correlated to the well know 
Maillard reactions and paves the way to consider the use of 2,5-diamino-
1,4-benzoquinones as potentially safe dyes (e.g.: as pigments for foods or 









4.3. Experimental section 
 
Solvents and starting materials were purchased from Sigma-Aldrich, Carlo 
Erba Reagents or TCI Europe and used without further purification. All 
aqueous solutions were prepared from ultrapure laboratory grade water 
(18 MΩ・cm) obtained from Millipore/MilliQ purification system. 1H and 13C 
NMR spectra were recorded at 300 MHz on a Jeol Eclipse ECP300 
spectrometer. Chemical shifts are reported in ppm with the protic impurities 
of the deuterated solvent as the internal reference. All NMR spectra were 
conducted at 333 K. Mass spectra were obtained with a TSQ Quantum 
Access Max Triple Quadrupole Mass Spectrometer (Thermo Scientific) 
equipped with an electrospray ionization (ESI) source; analysis by direct 
infusion.  High resolution mass spectra were registered on a Thermo Fisher 
Scientific Orbitrap Q-Exactive Plus mass spectrometer (San Josè, CA, 
USA), with 70.000 as resolution (FWHM) and methanol as solvent for 
infusion. All spectra were registered in positive ion mode. Chromatographic 
analyses were performed using a Thermo Fisher Scientific TRACE 1300 
gas chromatography system with Flame Ionization Detector, the apparatus 
used was equipped with a split/splitless injector and column TG-WAXMS 
(30 m x 0.25 mm i.d. x 0.25 µm film thickness). Separation was performed 
starting at 50 °C, held for 2 min, temperature increased at a rate of 10 
°C/min to 180 °C, temperature increased at a rate of 15 °C/min to 240 °C 
and finally held for 10 min. Analysis was performed at 1.5 mL min -1 
constant flow; hydrogen is the carrier gas. Injection temperature: 250 °C. 
Detector temperature: 350 °C Analysis was performed with 50:1 split ratio. 
TLC were performed with silica gel (MN Kieselgel 60F254) and visualized 










Vanillin (1.00 g, 6.57 mmol, 1.0 eq) was dissolved in ethanol (10 mL), then 
the corresponding amine (3.2 eq) was added, and the resulting solution 
was stirred in an open flask at room temperature for 16 hours. The obtained 
crystals were collected by filtration under vacuum and dried in air. 
 
The reaction with L-proline was carried out using the same procedure, 
adding sodium carbonate (2.2 eq) to the reaction mixture. The reaction 
progress was monitored by TLC then HCl 2M was added until pH 1. The 
resulting precipitate was filtered and dried in air. 
 
MTT assay were conducted following the procedure below: 
Human cell lines (HepG2, HEK293T) were cultured according to the ATCC 
guidelines. For cytotoxicity assays, cells were re-suspended in Dulbecco 
Modified Eagle Medium (DMEM) without phenol red, supplemented with 
10% heat-inactivated fetal calf serum. Cells were plated in 96-well 
polystyrene cell culture plates (30,000 to 50,000 cells/well depending on 
the cell type) and incubated at 37 °C in 5% CO2 for 24 hours to promote 
cell adhesion to the well’s surface. Compounds, with exception of 3f which 
was re-suspended in cell culture media (DMEM), were solubilized in DMSO 
at 1M concentration. Cells were incubated at 37 °C in 5% CO2 for 12 hours 
at concentrations ranging between 100 nM up to 100 µM. Experiments 
were performed in Locke solution (134 mM NaCl, 5 mM KCl, 4 mM 
NaHCO3, 10 mM HEPES [pH 7.6], 2.3 mM CaCl2, 1 mM MgCl2, 5 mM 
sucrose) with a final concentration of 250 µg/ml of the tetrazolium dye 3-




cells were washed twice in Locke to be incubated for 1 h with MTT at 37°C. 
Reactions were then stopped and the formazan crystals produced by 
cellular oxidoreductase enzymes were solubilized in isopropyl alcohol/HCl 









2,5-Dimorpholinocyclohexa-2,5-diene-1,4-dione (3a), brick-red solid, m.p.: 
239 - 240 °C (238 - 243 °C)21, yield: 83%): 1H NMR (300 MHz, CDCl3): δ 5.52 (s, 
2H), 3.79 (t, J = 4.3 Hz, 8H), 3.55 (t, J = 4.3 Hz, 8H) ppm. 13C NMR (75.6 MHz, 
CDCl3): δ 182.8 (C), 152.2 (C), 106.9 (CH), 66.5 (CH2), 49.1 (CH2) ppm. MS: Calc. 
[C14H18N2O4+H]+: 279.13393, found 279.13362, calc. [C14H18N2O4+Na] +: 
301.11588, found 301.11542. 
 
 
2,5-Di(piperidin-1-yl)cyclohexa-2,5-diene-1,4-dione (3b), dark-red solid, m.p: 
173 - 175 °C (176 °C)13, yield: 77%: 1H NMR (300 MHz, CDCl3): δ 5.44 (s, 2H), 
3.47 (br s, 8H), 1.60 (br s, 12H) ppm. 13C NMR (75.6 MHz, CDCl3): δ 182.6 (C), 
153.0 (C), 105.5 (CH), 50.2 (CH2), 25.9 (CH2), 24.3 (CH2) ppm. MS: Calc. 
[C16H22N2O2+H]+: 275.17540, found 275.17438. calc. [C16H22N2O2+Na]+: 










2,5-Di(azepan-1-yl)cyclohexa-2,5-diene-1,4-dione (3c), brick-red solid, m.p.: 
157 °C (157 °C), yield: 69%. 1H NMR (300 MHz, CDCl3): δ 5.32 (s, 2H), 3.62 (t, J 
= 5.9 Hz, 8H), 1.74 (br s, 8H), 1.50 (d, J = 9.5 Hz, 8H) ppm. 13C NMR (75.6 MHz, 
CDCl3): δ 181.8 (C), 151.5 (C), 101.3 (CH), 52.4 (CH2), 27.7 (CH2), 26.8 (CH2) 
ppm.  MS: Calc. [C18H26N2O2+H]+: 303.20670, found 303.20618. Calc. 
[C18H26N2O2+Na] +: 325.18865, found 325.18802. 
 
 
2,5-Di(pyrrolidin-1-yl)cyclohexa-2,5-diene-1,4-dione (3d), glittery red crystals, 
m.p.: 244 – 246 °C (238 - 240 °C)13, yield: 80%. 1H NMR (300 MHz, CDCl3): δ 
5.28 (s, 2H), 3.64 (br s, 8H), 1.91 (m, 8H) ppm. 13C NMR (75.6 MHz, CDCl3): δ 
180.6 (C), 149.8 (C), 100.0 (CH), 50.9 (CH2), 25.3 (CH2) ppm. MS: Calc. 
[C14H18N2O2+H]+: 247.14410, found 247.14371. Calc [C14H18N2O2+Na]+: 










2,5-Bis(dimethylamino)cyclohexa-2,5-diene-1,4-dione (3e), dark-red solid, 
m.p.: 156.6 °C (171-172 °C)21, yield: 86%: 1H NMR (300 MHz, CDCl3): δ 5.30 (s, 
2H), 3.14 (s, 12 H) ppm. 13C NMR (75.6 f  MHz, CDCl3): δ 181.7 (C), 152.3 (C), 
102.2 (CH), 42.5 (CH3) ppm.  MS: Calc. [C10H14N2O2+H]+ :195.11280, found 





L-2,5-Diprolincyclohexa-2,5-diene-1,4-dione (3f), brick-red solid, m.p.:  385 °C 
dec, yield 65%. 1H NMR (300 MHz, D2O): δ 5.20 (s, 2H), 4.74 (br s, 2H), 3.47 (br 
s, 4H), 218 – 1.78 (m, 8H) ppm. 13C NMR (75.6 MHz, D2O): δ 180.2 (C), 180.0 
(C), 151.2 (C), 99.7 (CH), 66.5 (CH), 52.3 (CH2), 32.0 (CH2), 22.0 (CH2) ppm. MS: 
Calc. [C16H18N2O6+H]+: 335.12376, found 335.12326. Calc. [C16H18N2O6+Na]+: 














Figure 4.3: Top: GC trace of the reaction mixture vanillin – morpholine. 
Bottom, GC trace of standard N-formylmorpholine (TCI Europe F0157) 
 
Figure 4.4: Top: GC trace of the reaction mixture vanillin – 
dimethylamine. Bottom, GC trace of standard N,N-dimethylformamide 
















Figure 4.5: MTT cytotoxicity tests. Dose-response curves of Hep G2 (top) 
and HEK293 (bottom) human cell lines treated with increasing 
concentrations of each compound (1 nM – 100 µM). Results are expressed 
as percent reduction vs vehicle- (DMEM or 0.1% DMSO) treated cells. 
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Catalysts play a central role during reactions, decreasing the activation 
energy barrier of the reagents and leading to the desired products easier 
and faster than for un-catalysed reactions. These goals are very important 
aspects for industries continuously involved in the development of new 
processes related to decrease of production costs.  
Catalysis in chemistry may be divided in: 
- Homogeneous catalysis  
- Heterogeneous catalysis 
Homogeneous catalysis involves the presence of organic or inorganic 
catalysts in the same phase of the reagents, generally represented by the 
liquid phase. On the other hand, heterogeneous catalysis involves the use 
of a catalyst linked to an inorganic and inert support; the catalyst and the 
reagents are then in two distinct different phases.  
Heterogeneous catalysis offers different advantages over homogeneous 
catalysis, among them an easy workup facilitated by the straightforward 
separation of the catalyst from the reaction mixture.  
Different inorganic supports are used depending on their specific 
properties like surface area, chemical stability and pore size. 
The principal materials used as supports in catalysis are: 
- alumina (aluminium oxide, in its different versions) 
- silica (hydrated silicon dioxide), characterized by weakly Brønsted 
acidity 
- zeolites, aluminosilicates characterized by well-defined pore sizes1 




aluminophosphates, silicoaluminophosphates (SAPO) or MCM-
type (mesoporous support) 
- MOFs (Metal-Organic-Frameworks) three-dimensional networks of 
metals bound to bi/tridentate-organic molecules 
- Organic polymers and copolymers as polystyrene/divinylbenzene, 
cellulose, etc. 
 
Heterogenising a catalyst is a common strategy to transfer a well-
established activity showed by a homogeneous catalyst in heterogeneous 
phase catalysis. Nevertheless, heterogenisation of a homogeneous 
catalyst is not straightforward, as it requires to bind the catalyst (generally 
an organic species or a metal complex) to the inorganic support through a 
suitable linker (Figure 5.1). 
 
Figure 5.1: General scheme of heterogenisation of a catalyst 
 
The catalyst has to be endowed with a functional group, whose role is to 
react with the linker, usually represented by a homo- or hetero-bifunctional 
molecule of a predefined length. The functional group should be implanted 
in a remote position with respect to the catalytically active site, so to reduce 
any possible interference with it, and should present and orthogonal 





During the PhD project we focused our attention on a well-known catalyst, 
i.e.: 4-(N,N-dimethylamino)pyridine 1 (DMAP).  
DMAP is an organic compound widely used as nucleophilic catalyst in 
different types of organic reactions. This pyridine derivative shows a 
greater nucleophilicity than the parent heterocycle due to the resonance of 
the azine ring with the dimethylamino substituent (Figure 5.2): 
 
 
Figure 5.2: Resonance of DMAP, 1  
 
Examples of reactions accelerated by DMAP include the acylation of 
tertiary or generally hindered alcohols, DCC-mediated esterification and 
amidation of carboxylic acid2 and silylation of alcohols and so on, all of 
them extremely important for the preparation of APIs and many other 
chemicals. 
Nevertheless, the structure of DMAP does not offer any possibility for its 
direct binding to an inorganic support and we decided to explore the 
possibility to introduce a reactive functional group on this important catalyst 
as a viaticum to its heterogenisation. 
A literature search pointed out the paucity of direct functionalisation of 
DMAP, limited to the direct bromination using NBS3 or direct formylation 
promoted by litium salt4. 
The pyridine ring of DMAP is well known to be scarcely reactive towards 
electrophilic aromatic substitution, due to the electron withdrawing effect of 




somewhat the situation, pumping electron density in the ring through the 
mesomeric effect, overcoming the opposite inductive effect. In principle, it 
is possible to perform electrophilic aromatic substitutions, provided that the 
electrophile has a marked reactivity. 
In Chapter 3 we demonstrated the superelectrophilic character of the 
diacylminium ion generated in the Tscherniac-Einhorn reaction. We 
envisaged the possibility to take advantage of this remarkable reactivity to 
introduce a functionality on DMAP that could be really suitable for our 
original purpose. 
We applied the Tscherniac-Einhorn to DMAP using N-hydroxymethyl-
phthalimide as the amidoalkylating agent. As N-hydroxymethylphthalimide 
can be generated in situ by the reaction of phthalimide (2) and 
paraformaldehyde, we developed a one-pot procedure involving DMAP, 
phthalimide and paraformaldehyde, reacting in concentrated sulfuric acid 
at 70°C (Scheme 5.1).  
 
 
Scheme 5.1: Synthesis of DMAP derivative 
 
To our delight, the conversion of DMAP to a single product was completed 
in 5 h. Standard workup of the homogeneous reaction mixture lead to the 
isolation of a the analytically pure 3-monophthalimidoalkylated product (3) 




The phthalimide group was removed using hydrazine hydrate in refluxing 
ethanol for 4 h, giving after workup 3-(aminomethyl)-N,N-dimethylpyridin-
4-amine (4) in 74% yield (Figure 5.4). 
 
 
Scheme 5.4: Hydrolysis of the phthalimide group 
 
The structure of compound 4 exemplifies our goal: a DMAP bearing a 
single reactive functional group (primary aliphatic amine), in a relatively 
remote position with respect to the active site (the catalytically active site 
is the anular nitrogen atom and in this derivative the ortho (2,6) positions 
are kept free). 
We exploited these properties by reacting DMAP with triethoxysilylpropyl 
isocyanate 5 (Scheme 5.2), the latter playing the role of the linker and 
showing a reactive tail represented by the trialkoxysilyl group, routinely 
employed for the grafting to hydroxyl-rich material surfaces such as silica 
and derivatives thereof. 
 
 
Scheme 5.2: Grafting reaction between modified DMAP compound 4 and 












In this chapter we reported the successful design and synthesis of a 
functionalised derivative of the important catalyst DMAP, i.e.: 3-
aminomethyl-4-(N,N-dimethylamino)pyridine. The additional functional 
group has been exploited for the preparation of a silylated derivative, useful 
for grafting DMAP to an heterogenous inorganic support. The preparation 
of the functionalised DMAP was accomplished in two steps taking 
advantage of the strong electrophile involved in the Tscherniac-Einhorn 
reaction. The desired product is obtained in high yields and avoiding 
chromatographic separations, optimal prerequisites for a future large-scale 
preparation. 
Future development of this work will deal with the grafting of the 
functionalised DMAP to silica-based inorganic supports for the preparation 
of organic-inorganic hybrid catalysts and with the evaluation of their 











5.3. Experimental Section 
 
Solvents and reagents. Commercially available solvents and reagents 
were used without further purification. When needed, the reactions were 
performed under positive pressure of nitrogen. 
NMR spectra were recorded using a JEOL ECP 300 MHz spectrometer. 
All NMR spectra were registered at 298 K. Chemical shifts (δ) are quoted 
to parts per million referenced to the residual solvent peak. The multiplicity 
of each signals is designated using the following abbreviations: s, singlet; 
d, doublet; t, triplet, q, quartet; quint, quintet; sext, sextet; sept, septet; m, 
multiplet, br s, broad singolet; br m, broad multiplet. Coupling constants (J) 
are reported in Hertz (Hz). Mass spectra were obtained with a TSQ 
Quantum Access Max Triple Quadrupole Mass Spectrometer (Thermo 
Scientific) equipped with an electrospray ionization (ESI) source; analysis 














In a round bottomed flask, conc. sulphuric acid (80 mL) was added and 
cooled to 0 °C with an ice/water bath. DMAP, 1 (15.0 g, 0.123 mol, 1.00 
eq) was added in small portions. Phthalimide, 2 (21.70 g, 0.147 mol, 1.20 
eq) and paraformaldehyde (5.53 g, 0.184 mol, 1.50 eq) were added and 
the mixture was heated at 70 °C for 5 hours. After complete conversion 
(TLC: DCM/ MeOH: conc. NH4OH 92/8/0.2), the mixture was cautiously 
poured in cold water and slowly basified to pH = 10 with Na2CO3. A white 
solid is formed and removed by filtration under vacuum, washed with 
distilled water and dried in air to constant weight (yield 94%). 
1H (300 MHz, CDCl3): δ 8.24 (d, J= 5.5 Hz, 1H), 8.11 (s, 1H), 7.80 (m, 2H), 
7.68 (m, 2H), 6.77 (d, J= 5.7 Hz, 1H), 4.87 (s, 2H), 2.81 (s, 6H) ppm. 
13C-APT (75 MHz, CDCl3): δ 168.1, 158.3, 149.5, 149.0, 134.4, 132.0, 
123.5, 123.2, 112.5, 43.5, 36.4 ppm. 
Calculated mass: C16H15N3O2: 281.31, found: 282.54. Calculated mass: 










In a 2 necked 500 mL round bottomed flask, compound 3 (30.0 g, 0.107 
mol, 1.00 eq) was suspended in ethanol (250 mL). Hydrazine hydrate (6.66 
mL, 0.149 mol, 1.4 eq) was added and the mixture was heated to reflux for 
4 hours. After complete hydrazinolysis (TLC: DCM/MeOH/conc. NH4OH 
92/8/0.2), the mixture was cooled to room temperature using an ice/water 
bath and the precipitate was filtered off and the mother liquors discarded. 
The solid was dissolved in 120 mL of warm NaOH 30% and extracted with 
toluene (6x50 mL). The organic extracts were dried on sodium carbonate, 
filtered and concentrated under vacuum to give the product ad a yellow oil 
(yield 74%).  
1H (300 MHz, CDCl3): δ 8.04 (s, 1H), 7.95 (d, J= 5.2 Hz, 1H), 6.42 (d, J= 
5.2 Hz, 1H), 3.58 (s, 2H), 2.53 (s, 6H) ppm.  
13C-APT (75 MHz, CDCl3): δ 157.0, 150.0, 148.3, 128.0, 111.2, 42.2, 41.4 
ppm.  
Calculated mass: C8H13N3: 151.21, found: 152.30. Calculated mass: 











In a round bottomed flask, 3-(aminomethyl)-4-(N,N-
dimethylamino)pyridine 4 (1.00 g, 0.0066 mol, 1.00 eq) was dissolved 
under nitrogen atmosphere in dry DCM (10 mL). Triethoxysilylpropyl 
isocyanate 5 (1.72 g, 0.0069 mol, 1.00 eq) was added in one portion. The 
resulting solution was kept at room temperature and, after 15 minutes, TLC 
analysis (DCM/ MeOH 8/2) showed complete conversion. The reaction 
mixture was concentrated under vacuum to give the product as a white 
solid (yield 96%).  
1H (300 MHz, CDCl3): δ 8.20 (s, 1H), 8.11 (d, J= 5.5 Hz, 1H), 6.61 (d, J= 
5.5 Hz, 1H), 5.67 (bs, 1 NH), 5.60 (bs, 1H), 4.31 (d, J= 5.2 Hz, 2H), 3.71 
(q, 6H), 3.09 (q, J= 7.0 Hz, 2H), 2.74 (s, 6H), 1.50 (q, J= 7.7 Hz, 2H), 1.12 
(t, J= 7.0 Hz, 9H), 0.54 (t, J= 8.2 Hz, 2H) ppm 
13C-APT (75 MHz, CDCl3): δ 158.7, 157.8, 150.3, 148.8, 125.1, 111.7, 
54.4, 42.9, 42.8, 39.6, 23.7, 18.3, 7.7 ppm 
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Major Depressive Disorder (MDD) is a complex mental disease 
characterized by loss of interest, esteem, low energy, anxiety and irritability 
and other symptoms. This pathology is the third global disease affecting 
more than 350 million people worldwide each year and negatively 
conditioning their normal life.1 
The causes of MDD is yet unknown although some hypothesis are raised 
on the genesis of the pathology, such for example dietary programs, stress, 
drug abuse, genetic factors and childhood abuse.2 This pathology is 
serious because it can lead to death by suicide. The onset of this disease 
arises at 25 years old to reach the maximum level at 40s and women are 
more susceptible to MDD than men, generally. There is never a complete 
regression of this pathology, and after many years, second or more 
episodes of depression may occur.  
The mental equilibrium is finely regulated by different substances called 
neurotransmitters. In particular, monoaminergic neurotransmitters as 
serotonin, norepinephrine, dopamine and adrenaline play a central role in 
this regulation, leading to the hypothesis of the monoaminergic deficit for 
the onset of this disease. It has been demonstrated that increasing the 
monoaminergic level inside the central nervous system (CNS) decreases 
the symptoms associated to MDD. On the base of this theory, different 







The most important APIs developed are drugs which act as inhibitor of 
monoaminergic re-uptake pathway. In particular, three different inhibitors 
were developed3: 
- SSRIs (selective serotonin re-uptake inhibitors) act on transporters 
devoted to the re-uptake of serotonin neurotransmitter (SERT). This 
class includes drugs such as fluoxetine, paroxetine, citalopram and 
many others. 
- SNaRIs (serotonin-nonepinephrine re-uptake inhibitors) act on two 
transporters devoted to the re-uptake of serotonin and 
norepinephrine neurotransmitter (SERT and NET). At this class 
belong drugs such as duloxetine and venlafaxine. 
- NRIs (selective nonepinephrine re-uptake inhibitors) act on 
transporters devoted the re-uptake of norepinephrine 
neurotransmitter (NET). At this class belong drugs such as 
viloxazine. 
 
Tricyclic antidepressants (TCA) such as amitriptyline and imipramine can 
be used for the treatment of MDD, too. These APIs molecules are 
unselective antagonists of the serotonin receptor, the muscarinic receptor 
and the histamine receptors, leading to several and serious side effect. For 
this reason, TCAs have been displaced by SSRIs and SNaRIs due to their 
better safety profile2.  
Alternative therapies target monoamine oxidases (MAO-A and MAO-B), 
enzymes involved in oxidative deamination of monoaminergic 
neurotransmitters. These enzymes are probably involved in other 




body dementia4. To this class belongs drugs like selegiline, moclobemide 
and iproniazid. 
Another important family of APIs used for the treatment of depression is 
that of the azapirones. These molecules act as partial agonists of 
postsynaptic 5-HT1A receptors, increasing the concentration/level of 
serotonin4. Generally, these types of drugs are used as add-on5 for the 
MDD patients with inadequate response to one of the previously described 
classes. The main representatives of this family are gepirone (1), 
buspirone (2), and tandospirone(3)6,7 (Figure 6.1). 
 
 
Figure 6.1: The family of azapirones 
 
Azapirones share three common structural features: 
- the 2-(1-piperazinyl)pyrimidine double ring system; 
- a 4-carbon chain (n-butyl) acting as a linker 
- a 5- or 6-membered cyclic or bicyclic imide 
 
Although the scientific literature lists several papers and patent on the 
synthesis and bioactivity of these molecules, scarce information is 
available for the solid-state properties of the azapirone family, with only a 




6.2. Discussion and Results 
 
During the PhD, we focused our attention on gepirone with the aim to 
characterise the crystal forms of this API and to investigate the eventual 
presence of additional polymorphs. The solid state behaviour of gepirone 
hydrochloride is mentioned in a single article by Behme et al.8 In detail, 
they reported the evidence of three distinct polymorphs named: form I, form 
II and form III. DSC analysis revealed that form I has melting point at 180 
°C, form II 212 °C and form III 200 °C. As the study is based on thermal 
analysis only, no structural data is reported in this manuscript for the three 
claimed polymorphs. 
In order to confirm or integrate the information on the polymorph of 
gepirone hydrochloride and to extract the structural parameters of all its 
solid-state forms, we undertook a comprehensive study on this API. 
The investigation of additional polymorphs was focused on free base, too. 
The study of free base is important for the sake of comparison with the 
hydrochloride form, in order to gain information on the microscopic 
protonation site and the conformational changes determined by this 
process. 
Several attempts were made, employing different solvents for the 
crystallization of gepirone free base and the hydrochloride form. 
Gepirone free base was crystallised using solvents such as: 








Gepirone free base crystallizes in the monoclinic P21/c space group, with 
one molecule in general position (Figure 6.2). The conformation of the 
molecule is quite planar, mainly due to the fully extended chain 
conformation of the butyl C4 spacer. Only one weak inter-molecular 
interactions may be found and it is of the type C-H…N between a methylene 
group of the glutarimide portion and the nitrogen atom of the piperazine 
ring linked to the butyl chain (H-bond distance is 3.592 Å). The piperazine 
ring is found to be in the chair conformation. Conformation of the whole 
molecule, and crystallographic details (i.e.: space group, unit cell volume) 
are found to be quite similar to the ones reported in the literature for 
buspirone free base9.   
 
 
Figure 6.2: Crystal packing of gepirone free base viewed down to the 
[010] crystallographic direction. Colour code: N, blue; O, red; C, gray; H, 





Figure 6.3. Depiction of the weak interactions of the type C-H…N 
between gepirone molecules in the crystal lattice. Colour code: N, blue; 
O, red; C, gray; H, white. Ellipsoids are depicted at the 50% probability 
level. 
 
The thermal behavior of gepirone free base was elucidated by means of 
Differential Scanning Calorimetry (DSC) and in situ variable-temperature 
X-ray diffraction analysis. The DSC curve shows that there are no other 
thermal events other than the melting of the form at about 110 °C. Gepirone 





Figure 6.4: DSC analysis of gepirone free base 
 
Gepirone free base was further analysed by variable temperature XRD 
analysis (Figure. 6.5). Data were collected up to amorphization of the 
sample. While rising the temperature an effect of induced preferential 
orientation is observed, with the reflection at about 2θ 18.5 ° that becomes 
sharper. This is probably due to fusion-recrystallization of small crystallites 
on the sample holder. No other phenomena are observed, in agreement 






Figure 6.5:  Variable-temperature XRPD analysis of gepirone free base. 
 
The study of gepirone hydrochloride started with an acquisition of the DSC 
curve (Figure 6.6), in order to confirm the behaviour observed by Behme8 
for our samples of this API or possibly to highlight eventual differences. 
 
 




The DSC analysis of our sample of gepirone hydrochloride paralleled the 
curve reported by Behme8, with the clear evidence three thermal events 
attributable to three crystal forms: form I, form III and form II, respectively.  
Crystals of gepirone hydrochloride (Form I) suitable for single crystal X-ray 
diffraction were obtained heating gepirone hydrochloride in acetonitrile 
until dissolution. The clear solution was kept at 22-25 °C until the formation 
of the crystals. The analysis of these crystals revealed that gepirone 
hydrochloride form I belongs to the monoclinic P21/c space group with one 
molecule in general position (Figure 6.7).  
 
Figure 6.7:  Crystal packing for gepirone hydrochloride form I viewed 
down to the [100] direction. Colour code: Cl, green; N, blue; O, red; C, 
gray; H, white. Ellipsoids are depicted at the 50% probability level. Three 
of the four molecules in the unit cell have been coloured for helping the 
reader in the visualization of the structure. 
 
Gepirone hydrochloride presents the (HCl) acid proton bonded to a 
nitrogen atom of the piperazine ring. As expected, the protonation electron 




butyl chain. The opposite nitrogen atom, linked to the pyrimidine ring, has 
its lone pair involved in the resonance with the heteroaromatic ring, thus 
strongly reducing its basicity. 
Moreover, the overall molecular conformation of gepirone hydrochloride is 
quite different from that observed for the free base. Figure 6.8 clearly 
shows the effect of the protonation in Form I, that may be summarized in 
the loss of the extended chain conformation of the butyl chain spacer, the 




Figure 6.8: Depiction of the asymmetric unit for Gepirone HCl form I to 
highlight the conformation of the molecule. Colour code: Cl, green; N, 
blue; O, red; C, gray; H, white. Ellipsoids are depicted at the 50% 
probability level. 
 
The chlorine atom is the centre of several interactions, among them the 
hydrogen bond N-H∙∙∙Cl with the protonated nitrogen atom of the and 
additional short contacts with hydrogen atoms of methylene groups of the 




While performing the in situ variable temperature X-ray powder diffraction 
experiment, after the melting of form I, we were able to observe the 
recrystallization of the sample in small crystals, which were found to be of 
a quality suitable to perform a single crystal XRD analysis. This allowed us 
to retrieve the crystal structure information for the second polymorph of 
gepirone HCl, which as later recognized as form II previously claimed by 
Behme8 with no associated structural data.  
The form II of gepirone hydrochloride crystallizes in the P212121 
orthorhombic space group, still with one molecule in general position 
(Figure 6.9). 
 
Figure 6.9: Crystal packing for gepirone hydrochloride form II, viewed 
down to the [100] crystallographic direction. Colour code: Cl, green; N, 
blue; O, red; C, gray; H, white. Ellipsoids are depicted at the 50% 
probability level. 
 
In Figure 6.10 it is possible to note that this high melting point form II is 
endowed with more intermolecular interactions than those observed in 






Figure 6.10: H-bond and close contacts pattern (in blue dotted lines) for 
gepirone hydrochloride, form II. Colour code: Cl, green; N, blue; O, red; 
C, gray; H, white. Ellipsoids are depicted at the 50% probability level. 
 
The chlorine atom is still interested in an H-bond with the protonated 
nitrogen of the piperazine ring, while short contacts may be found involving 
three out of four methylene groups of the butyl chain, methylene groups of 
the piperazine ring, one C-H of the pyrimidine ring and the oxygen atoms 
of the carbonyl groups of the glutarimide portion. 
Figure 6.11a-b, shows the comparison between the conformations of the 
two molecules of gepirone hydrochloride in form I and form II, respectively. 
While the pyrimidine-piperazine system appears to be substantially 
unchanged, the main variation may be ascribed to the aliphatic C4 chain, 
wrapped in Form I and extended in Form II. The different conformation of 






Figure 6.11: Comparison between the conformations of the two 
molecules in a) gepirone HCl form I and b) gepirone HCl form II. The 
molecules are oriented keeping fixed the chair conformation of the 
piperazine ring. Colour code: Cl, green; N, blue; O, red; C, gray; H, white. 
Ellipsoids are depicted at the 50% probability level. 
 
Figure 6.12: Variable temperature X-ray powder diffraction analysis. 
Bottom to up, from room temperature up to complete transformation of 
the form I into the form II. Blu patterns correspond to form I; green pattern 





The variable temperature PXRD analysis reported in Figure 6.12 clearly 
shows the thermal evolution of the initial Form I, finally leading at high 
temperatures (220°C) to pure Form II. Signals of the transient Form III may 
be detected at 200°C, as indicated by the DSC analysis, but Form III is 
always accompanied by variable amounts of Form II, the latter being 
predominant and even exclusive at higher temperatures. The transience of 
Form III is probably the reason of our failure to isolate crystals of this form. 
 
Crystallographic data obtained for gepirone free base and for gepirone 





    Form I Form II FB 
Formula    C19H30N5O2Cl C19H30N5O2Cl C19H29N5O2 
Fw    395.9 395.9 359.47 
System    Monoclinic Orthorhombic Monoclinic 
Space Group    P21/c P212121 P21/c 
a, Å    13.9240(9) 6.146(3) 10.1000(16) 
b, Å    12.2460(8) 10.897(6) 11.7068(19) 
c, Å    12.1075(8) 32.823(17) 16.800(3) 
α, °    90 90 90 
β, °    90.6090(10) 90 95.718(3) 
γ, °    90 90 90 
V, Å3    2064.4(2) 2198(2) 1976.5(5) 
Z    4 4 4 
Temperature (K)    293(2) 293(2) 293(2) 
ρ(calcd), g cm-3    1.274 1.196 1.208 
μ, mm-1    0.209 0.074 0.081 
F(000)    848 848 776 









θ range for data 
collection, deg 
   1.463-24.759 1.969-23.182 2.026-22.013 
limiting indices    -16 ≤ h ≤ 6 
-14 ≤ k ≤ 14 
-14 ≤ l ≤ 14 
-6 ≤ h ≤ 6 
-12 ≤ k ≤ 12 
-36 ≤ l ≤ 36 
-10 ≤ h ≤ 10 
-12 ≤ k ≤ 12 
-17 ≤ l ≤ 17 
reflns 
collected/unique 





[Rint = 0.0417] 
final R indices  
[I > 2σ(I)] 
   R1 =  0.0377 
wR2 =  0.0316 
R1 = 0.0438 
wR2 = 0.806 
R1 = 0.0396 
wR2 = 0.0699 
R indices (all data)    R1 = 0.0876 
wR2 = 0.0832 
R1 = 0.0793 
wR2 = 0.0889 
R1 = 0.0880 
wR2 = 0.1000 
GOF on F2 c    1.079 0.976 1.010 
largest diff peak and 
hole, e Å−3 









a Rint = Σ|Fo2 − Fo2(mean)|/ΣFo2, Rσ = Σσ(Fo2)/ΣFo2, R1 = Σ||Fo| − |Fc||/Σ|Fo|, wR2 = {Σ[w(Fo2 
− Fc2)2]/Σ[w(Fo2)2]}1/2, GOF = {S/(n −p)}1/2 = {Σ[w(Fo2 − Fc2)2]/(n − p)}1/2. 
Table 6.1: Crystallographic data for gepirone hydrochloride, Form I and 
















In this chapter, we focused our attention on the solid-state properties of 
gepirone hydrochloride, in order to obtain further information about its 
crystalline form and the presence of others polymorphic forms. 
In 1985, Behme et al.8 reported the alleged presence of three polymorphic 
forms (Form I, II and III) of gepirone hydrochloride. The form I is reported 
to melt at 180°C, form II at 212 °C and form III at 200 °C. Unfortunately, no 
structural data for these forms were reported as their existence was 
ascertained only by DSC analysis. 
Thermal analysis on our samples of gepirone hydrochloride confirmed the 
presence of three forms of this API and we succeeded in isolating crystals 
of two of these forms, along with crystals of the free base. Single crystal X-
ray diffraction analysis of these forms allowed to obtain detailed structural 
information. In addition, variable temperature PXRD studies defined the 












6.4. Experimental Section 
 
Gepirone compound was prepared following the literature reported 
methods10-13. 
Then, several crystallisations tests were made in order to obtain suitable 
crystals for the X-ray analysis. In particular, we focused our attention on: 
- Gepirone free base  
- Gepirone HCl (commercial form) 
 
The free base form was added in 3 mL of the appropriate solvent (MIBK) 
and dissolved by heating. The obtained solution was kept at 22 – 25 °C 
until crystals, suitable for X-ray analyses, were obtained. 
 
Gepirone hydrochloride was suspended in 3 mL of acetonitrile and 
dissolved by heating. The resulting solution was kept at 22 – 25 °C until 
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Idiopathic Pulmonary Fibrosis (IPF) is a debilitating lungs disease 
characterised by cough, scars and dyspnoea that lead to progressive 
degeneration of lungs reaching an irreversible loss of function. This 
pathology is common in patients over 60 years’ old, and male patient are 
more affected1. After the diagnosis of this pathology, the life expectancy is 
drastically reduced to few years, generally 3-5 years2 without lung 
transplantation. 
In 2019 in USA and Europe, more than 100.000 peoples are affected by 
IPF, but detailed data, today, are scarcely available. This serious 
pathology, is associated to different risk factors like cigarettes smoke, 
sarcoidosis and various genetic factors3. 
Pirfenidone is to date the only API used for the treatment of IPF. It was 
approved Japan in 2008 (trade mark Pirespa®) and in Europe in 2011 
(trade mark Esbriet®). Pirfenidone (IUPAC name: 5-methyl-1-phenyl-1H-
pyridin-2-one) is a heterocyclic compound with a 2-pyridone ring with a N-
phenyl substituent and a methyl group in position 5, being a small and very 
simple molecule. 
Pirfenidone (Figure 7.1) shows a well-known activity as anti-fibrotic and 
anti-inflammatory compound4. Moreover, this API, reduces fibroblast 
proliferation5 and it is able to interact with other proteins like TGF-β, and 
other cytokines5, but the exact molecular target has not been highlighted. 
Several clinical studies were directed to understand the mechanism of 
action, safety profile, and other important parameters (bioavailability, dose, 




tolerated7 leading this molecule as the only lead compound in the treatment 
of IPF. 
Different synthetic procedure for the synthesis of pirfenidone are reported 
in the scientific literature8-12, but much less is reported on the solid state 
properties, of this important API. As mentioned in the chapter 1, the 
presence of one or more crystalline forms may affect significantly the 




Figure 7.1: Molecular structure of pirfenidone 
 
Our work was focused on the screening of the eventual crystalline forms 
of pirfenidone, gaining a comprehensive solid-state characterisation of this 
molecule. To this purpose a systematic series of experiments involving the 
crystallization of pirfenidone from different solvents (alcohols, acetone, 
acetonitrile, nitromethane, toluene) were performed. 
The starting material pirfenidone was prepared according to a previously 
reported method8, with a purity >99.5 %.  
Although various solvents and mixtures thereof produced a crystalline 
precipitate of pirfenidone, large transparent crystals suitable for SCXRD 





Data of the pirfenidone crystal, collection and structure refinement details 
are summarized in Table 7.1. The crystals of pirfenidone belong to the 






Chemical Formula C12H11NO 
Mr 185.22 
Crystal system, space group Monoclinic, P21 
Temperature (K) 293 
a (Å) 6.2525(8) 
b (Å) 7.797(1) 
c (Å) 10.2810(13) 
α, β, γ (°) 90, 104.744(2), 90 
V (Å3) 484.70(11) 
Z 2 
Radiation type Mo Kα 
μ (mm-1) 0.08 
Crystal size (mm) 0.5 x 0.45 x 0.05 
Data Collection  
Diffractometer Bruker SMART APEX CCD 
Absorption correction Multi-scan (SADABS; Bruker, 2010) 
Tmin; Tmax 0.692, 0.746 
No of measured, independent and observed 
 [I > 2σ(I)] reflections 
4547, 2128, 1879 
Rint 0.019 
(sin θ/λ)max (Å-1) 0.643 
Refinement  
R[F2 > 2σ(F2)], wR(F2), S 0.037, 0.095, 1.04 
No. of refelctions 2128 
No. of parameters 127 
No. of restraints 1 
H-atom treatment H-atom parameters constrained 
Δρmax, Δρmin, (e Å-3) 0.11, -.20 
Absolute structure Flack x determined using 762 quotients 
[(I+)-(I-)]/(I+)+(I-) 
Absolute structure parameters 0.3 (4) 
 





 The phenyl substituent and the pyridinone ring are not coplanar (Figure 
7.2), subtending a dihedral angle of 50.30(11) and implying a negligible 
resonance between the two -systems. 
 
Figure 7.2: Molecular structure of pirfenidone 
 
In the crystal, pirfenidone molecules are linked in the crystal by C—H∙∙∙O 
pseudo-hydrogen bonds with the same acceptor atom, generating an 
undulating network, enclosing R34 (20) ring motifs, parallel to the ab plane 
(Figs. 7.3 and 7.4). No additional significant intermolecular contacts may 






Figure 7.3: View of CH∙∙∙O interactions in the crystal packing of 
pirfenidone 
 
Figure 7.4: View of the undulating network of CH∙∙∙O interaction in the 




Finally, the PXRD pattern calculated on the base of the SCRXD data was 
compared with the PXRD pattern registered on a sample of commercial 
pirfenidone powder, prepared according to the reported procedure.8 The 
very good agreement implies that the crystal phase of the commercial 








Figure 7.5: Comparison of PXRD patterns of 
pirfenidone. Red line = experimental pattern of a 
commercial sample. Blue line = calculated pattern based 



































In conclusion, in this work we investigated the solid-state features of 
pirfenidone. A thorough screening of solvents and mixtures thereof, 
allowed to identify a single crystal phase for this specific API. No additional 
forms were isolated, nor were adducts, solvates or inclusion compounds. 
The structural details of the molecule of pirfenidone and its packing in the 
monoclinic crystal were determined by single-crystal X-ray analysis.14 
The limited number of polar residues and functional groups along with the 
few degrees of rotational freedom of this small molecule are likely at the 





7.3. Experimental Section 
 
Solvents and reagents. Commercially available solvents and reagents 
were used without further purification. 
Single crystal X-ray analysis. Bruker SMART APEX CCD diffractometer 
ω scans Absorption Correction: multi-scan (SADABS), Tmin = 0.692, Tmax = 
0.746, 4547 measured reflections. 
 
Computing details. Data collection: APEX2; cell refinement: SAINT; data 
reduction: SAINT; 
program(s) used to solve structure: SHELXT201715; program(s) used to 
refine structure: SHELXL201716; molecular graphics: ORTEP-3 for 
Windows17 and Mercury18; software used to prepare material for 
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Preparation of Pirfenidone single crystal 
 
Pirfenidone (approx. 100 mg) was heated in toluene (2 mL) until complete 
dissolution. The clear solution was closed and kept at 0-5 °C for one week 
obtaining colourless crystals of pirfenidone.  
The melting point determined through DSC is 383 K. 
 
The same protocol was applied with different solvents. The same crystal 
form was obtained in all instances. 
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Human infections are considered a priority for the public health but at the 
same time, animal infections are important as they can represent an 
additional vehicle for the transmission to humans. In particular, infections 
that affect cattle, horses and domestic pets like cats and dogs1,2 are 
especially dangerous as these animals live in close contact with peoples. 
Infections are caused by different type of macro or micro-organisms 
(parasites) able to attack all living species including humans and animals. 
Parasites can be broadly classified in two categories:  
- Endoparasites: living inside the body 
- Ectoparasites: living outside the body 
Parasites affecting humans and animals may be ascribed to all kingdoms 
of biology, with the addition of viruses. Animal infections like filariasis1, 
scabies3, ocular thelaziosis4, chagas, toxoplasmosis, leishmaniosis5 are 
the most represented pathologies with a worldwide diffusion. As a 
consequence, the veterinary market for livestock and pets, will increase by 
5.6% in next 5 years6 leading to an increase of the global vaccines 
production. 
Among human infections, a specific nematode, Onchocerca volvulus, is 
able to infect people leading to onchocerciasis, also known as “river 
blindness”, a particular disease ultimately leading to blindness7,8. This 
pathology is mainly localised in Africa, especially in sub-Saharan states 
and in a few other countries like Brazil and Venezuela, as reported by the 
World Health Organization. 
Ivermectin (Figure 8.1) and related molecules are the preferred treatment 
for onchocerciasis, as it is able to paralyse and kill the nematode. 
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Moreover, ivermectin is administered in a single dose, to be repeated after 
6 months, has a well-established safety profile and does not need 
refrigeration, facilitating the treatment in undeveloped countries where 
these pathologies are particularly spread. 
Ivermectin belongs to the avermectin class, 16-membered macrocyclic 
lactones with high potent anthelminthic activity. Avermectins were 
discovered by S. Omura, in collaboration with W.C. Campbell, in the mid-
1970s and these types of compounds were obtained by fermentation 
culture broth of Streptomyces avermectinius9. For this important discovery 
they jointly received in 2015 the Nobel Prize for medicine10. 
 
 
Figure 8.1: Ivermectin  
 
Ivermectin is a semisynthetic compound composed by mixture of 22,23-
dihydro derivatives of avermectins B1a and B1b, where –R is represented 
by –CH(CH3)CH2CH3 or –CH(CH3)2, respectively11.  These compounds are 
characterised by the presence of a glycoside on the macrocyclic lactone 
structure the latter embodying several unsaturated C=C bonds. 
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Moxidectin is a semisynthetic derivative of ivermectin, i.e. recently 
introduced for the treatment of onchocerciasis and of infections of cattle, 
horses and pets like dogs and cats. 
Moxidectin (Figure 8.2, IUPAC name ((6R,23E,25S)-5-O-demethyl-28-
deoxy-25-[(1E)-1,3-dimethyl-1-buten-1-yl]-6,28-epoxy-23-(methoxyimino) 
milbemycin B) is a semisynthetic 23-methoxime macrocyclic lactone, 
belonging to the milbemycin class12,13. The latter are produced by 
fermentation from Streptomyces cyaneogriseus. 
 
Figure 8.2: Moxidectin  
Moxidectin has a high similarity with ivermectin, the only differences being 
limited to the presence of the E-methoxime group on C-23 and E-4-
methylpent-2-enyl on C-25 and the absence of the disaccharide moiety on 
C-13.  
Due to the high activity as anthelmintic drug, moxidectin is employed today 
for the treatment of parasitic infection in humans, in particular for the 
treatment of the “river blindness” disease, after approval by FDA in 2018. 
Its activity is related to the blocking of glutamate-gated chloride ion channel 
leading to flaccid paralysis of the neuromuscular system of the 
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nematode14. Moreover, due to the low toxicity, moxidectin is employed as 
ectoparasiticide agent in agriculture. 
Thanks to the importance of moxidectin for human health, several articles 
have been reported in relation to its biological activity and its formulation. 
On the other hand, a comprehensive knowledge of the solid-state 
behaviour of this compound is lacking, as information on the single crystal 
structure and the presence of polymorphs, solvates and hydrates, are 
currently scarce. 
Beddall et al15 first disclosed the single crystal structure of “dry” 
(unsolvated) moxidectin, characterized by the orthorhombic P212121 space 
group. This form was named moxidectin form I and the details of the crystal 
structure are available in the CSD with the reference-code GETBOW 
(Figure 8.3). 
 
Figure 8.3: Crystal structure of “dry” (unsolvated) moxidectin  
 
Additional four forms, three solvates and amorphous forms, were claimed 
in a patent16 and identified by PXRD and DSC, even if the structural details 
are not disclosed (Table 8.1). 
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Crystal form Solvent First report 
Ref. for 
structure 
Moxidectin None Beddall et al GETBOW 
Moxidectin·2EtOH Ethanol WO2013/082373A1 
Not 
available 
Moxidectin·2iPA 2-Propanol WO2013/082373A1 
Not 
available 




Table 8.1: Summary of reported moxidectin crystal forms 
 
During the PhD, we started a systematic investigation on moxidectin, by 
crystallising the API from many solvents and in different experimental 
conditions and techniques.  
As a result of these efforts, we were able to obtain three distinct crystalline 
forms of moxidectin, suitable for single-crystal diffractometric analysis, all 
of them as solvates: 
1) Moxidectin solvate with ethanol (1:2) 
2) Moxidectin solvate with 2-propanol (1:2) 
3) Moxidectin solvate with nitromethane (1:1.5) 
The first two crystalline forms are useful to confirm the claim reported in 
the original patent16, while the nitromethane solvate is completely 
unprecedented and represents a new solvate. We were not able to obtain 
any crystal of the alleged butanol solvate, nor of the “dry” unsolvated form. 
Experimental details and crystallographic data of the three forms are 
reported in Table 8.2. 
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Fw 731.96 760.01 730.56 
System Monoclinic Monoclinic Orthorombic 
Space Group P21 P21 P21212 
a, Å 11.1958(11) 11.5256(90) 19.793(2) 
b, Å 8.8507(9) 9.1571(7) 13.9246(15) 
c, Å 21.968(2) 21.8144(16) 15.2689(16) 
α, ° 90 90 90 
β, ° 93.7(2) 93.0690(10) 90 
γ, ° 90 90 90 
V, Å3 2172.3(4) 2299.0(3) 4208.3(8) 
Z 2 2 4 
Temperature (K) 120(2) 293(2) 100(2) 
ρ(calcd), g cm-3 1.116 1.054 1.203 
μ, mm-1 0.079 0.074 0.089 
F(000) 792 792 1640 










θ range for data 
collection, deg 0.929-30.791 0.935-24.903 1.334-24.944 
limiting indices 
-16 ≤ h ≤ 15 
-12 ≤ k ≤ 12 
-31 ≤ l ≤ 31 
-13 ≤ h ≤ 13 
-10 ≤ k ≤ 10 
-25 ≤ l ≤ 25 
-23 ≤ h ≤ 23, 
-16 ≤ k ≤ 16 






[Rint = 0.0357] 
32062/7327 
[Rint = 0.0325] 
data/restraints/param 12892/1/473 7883/1/489 7327/0 /489 
final R indices 
[I > 2σ(I)] 
R1 = 0.0615 
wR2 = 
0.1429 
R1 = 0.0553 
wR2 = 0.1440 
R1 = 0.086 
wR2 = 0.2318 
R indices (all data) 
R1 = 0.0948 
wR2 = 
0.1591 
R1 = 0.0736 
wR2 = 0.1560 
R1 = 0.0941 
wR2 = 0.2390 
GOF on F2 c 1.039 1.056 1.059 
largest diff peak and 










a Rint = Σ|Fo2 − Fo2(mean)|/ΣFo2, Rσ = Σσ(Fo2)/ΣFo2, R1 = Σ||Fo| − |Fc||/Σ|Fo|, wR2 = {Σ[w(Fo2 − 
Fc2)2]/Σ[w(Fo2)2]}1/2, GOF = {S/(n −p)}1/2 = {Σ[w(Fo2 − Fc2)2]/(n − p)}1/2. 
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Moxidectin solvate with ethanol (hereinafter Moxi∙2EtOH) and moxidectin 
solvate with 2-propanol (hereinafter Moxi∙2iPrOH) are isostructural. 
Crystallographic description is here discussed only on the ethanol solvate, 
while the same considerations can be applied to the isopropanol solvate. 
Moxi∙2EtOH (Figures 8.4 and 8.5) crystallizes in the monoclinic space 
group P21 with one molecule of moxidectin in general position. Two ethanol 




Figure 8.4. Asymmetric unit for Moxi∙2EtOH crystal structure viewed 
down the [010] direction. Ellipsoids are depicted at 50% probability. 
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Figure 8.5.  Moxi∙2EtOH crystal packing viewed down to the [010] 
direction.  Ellipsoids are depicted at 50% probability. Colour codes: gray, 
carbon; light gray, hydrogen; red, oxygen; blue, nitrogen. 
 
An interesting H-bond pattern is found between solvent molecules and the 
OH groups of the hexahydrobenzofuran ring of the moxidectin molecule. 
Figure 8.6 (a and b) depicts the cyclic H-bond pattern found in the crystal 
packing. In these intermolecular H-bonds contacts, two ethanol molecules 
and two moxidectin molecules are involved; distances fall in the range 
2.70-2.78 Å. All H-bonds contacts are of the type –O-H…O- and are 
between Moxi-EtOH; EtOH-EtOH; EtOH-Moxi and Moxi-Moxi, 
respectively. More in detail, between O(7)H…O(EtOH1), 2.703 Å; 
(EtOH1)O-H…O(EtOH2), 2.731 Å; (EtOH2)O-H…O(8), 2.783 Å and 
O(8)H…O(7), 2.764 Å. The latter H-bond also bifurcates through the O 
atom of the furane ring (3.172 Å). Figure 8.6b shows an enlargement of the 
two hexahydrobenzofuran rings of two different moxidectin molecules and 
the two ethanol molecules with highlighted, in dotted blue lines, the cyclic 
intermolecular H-bond pattern. 
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Figure 8.6. a) Crystal packing around the H-bond pattern found in 
Moxi∙2EtOH solvate. B) Enlargement of the hexahydrobenzofuran rings 
which interact with the two ethanol molecules. Colour codes: C, gray; H, 
white; O, red; N, blue. H-bonds are highlighted in dotted lines. 
Slow evaporation of a nitromethane solution of moxidectin gave 
transparent flat platelets, which has been analysed by single-crystal X-ray 
diffraction. Moxi∙1.5MeNO2 crystallizes in the orthorhombic space group, 
whit one molecule in general position. Quality of the crystals was found to 
be low (max resolution 0.85Å at 100K), this was later ascribed to the 
disordered nitromethane molecules, which are all confined in a portion of 
the unit cell and disordered around the twofold axis (Figure 8.7). During the 
solution process of the structure, all attempts done for a description of the 
solvent molecules failed, due to the high degree of disorder and to the fact 
that multiple molecules are present, all with different occupancy factor. 
Indeed, we decided to use the SQUEEZE procedure, implemented in 
PLATON17. Squeeze gave rise to an 800 Å3 void volume in the unit cell, 
which correspond to the 20 % of the total cell volume, and a total number 
of 180 electrons coming from the solvent molecules, which are in good 
agreement for a 1.5 nitromethane molecule in the asymmetric unit. In figure 
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8.7 and 8.8 are depicted the moxidectin molecules packed in the unit cell 
and, in yellow, the residual void volume obtained with PLATON-SQUEEZE 
procedure, where the nitromethane molecules are found. 
 
Figure 8.7: Crystal packing of Moxi∙1.5MeNO2 viewed along the [001] 
crystallographic direction. For clarity, solvent molecules are omitted and, 
because space group of this crystal structure is P21212, three of the 4 
molecules in the unit cell are coloured in orange, green and blue. Colour 
codes for the 4th molecule are C, gray; N, blue; O, red; H, white. 
 
Figure 8.8: Void volume in the crystal packing after squeezing with 
PLATON. Voids account for 15% of the unit cell volume and about 660 
Å3, in good agreement with two MeNO2 molecules per formula unit.  
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It is worth to highlight here two H-bond contacts found in this crystal 
structure, which are not present in the other two solvates. Indeed, an 
intramolecular H-bond is found between the tertiary alcohol located on the 
bridgehead position of the fused bicylic[4.3.0] residue and the carbonyl 
group of the O=C of the type O-H…O= with distance 2.716 Å (Figure 8.9). 
This intra-molecular bond is not present in the iPrOH and EtOH solvates, 
in which the bridgehead OH of moxidectin participates in the H-bond 
pattern involving the solvent molecules.  
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Moreover, intermolecular H-bonds are found between two moxidectin 
molecules, and are depicted in Figure 8.9. Here the H-bonds are both of 
the same nature and are exchanged between the oxygen atom of the furan 
ring (O6) and the –OH group of the secondary alcohol located on the six-
membered carbocyclic ring of the hexahydrobenzofuran moiety. These are 
coupled between symmetry related (around the twofold axis) moxidectin 
molecules with distances 2.84 Å, in both cases.   
An insight into the solid-state behavior of moxidectin solvates was then 
determined by means of variable temperature X-ray powder diffraction 
experiments.  
As already discussed in the introduction, few information are reported in 
the literature regarding the formation of moxidectin crystals and moxidectin 
solvates. Even less information are reported in the possible mechanism of 
conversion between moxidectin and the corresponding solvates. In our 
study we analysed the behaviour of moxidectin solvates with in situ 
variable temperature powder X-ray diffraction analysis. With this 
technique, by using a custom-made conditioning chambers allowing to 
characterise the thermal behaviour of a sample under study, samples of 
moxidectin solvates were heated starting from room temperature up to 
decomposition. 
 
Figure 8.10: VT-PXRD plot, Moxi∙2MeNO2 
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Figure 8.10 reports the two-dimensional contour plot as a function of 2θ 
and temperature for the collection of powder X-ray diffraction patterns 
measured at increasing temperatures in the range 25-100 °C for 
Moxi∙2iPrOH. The collection of PXRD patterns shows that, by rising the 
temperature, the sample loses crystallinity at about 70 °C, and become 
amorphous. An experiment repeated up to 210 °C showed no thermal 
events (i.e.: crystallization to a crystalline not-solvated form) other than 
decomposition of the molecule. 
 
 
Figure 8.11: VT-PXRD plot, Moxi∙2MeNO2 
 
Figure 8.11 reports the two-dimensional contour plot as a function of 2θ 
and temperature for the collection of powder X-ray diffraction patterns 
measured at increasing temperatures in the range 25-100°C for 
Moxi∙2MeNO2. The collection of PXRD patterns shows that, by rising the 
temperature, the sample loses crystallinity at about 60°C and gradually 
become amorphous.  
As reported in Figure 8.10 and 8.11, following the loss of solvent molecules 
no evidence of the formation of a crystalline phase (i.e.: the expected 
unsolvated form previously reported15) is observed for Moxi∙2iPrOH and 
Moxi∙1.5MeNO2, respectively.  
Moreover, we tried to prove the accuracy of the purported mechanisms of 
interconversion between moxidectin forms (solvates and pure form), 
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reported in the patent WO2013/082373A116. To this purpose, we heated 
in situ the amorphous moxidectin from 170 to 200 °C for several hours (ca. 
5 h). No observation of a crystallization events was observed (see Figure 
8.12).  
 
Figure 8.12: Collection of diffractograms for moxidectin (amorphous 
form) heated, in a range time of 5 hours, from 170 °C to 200 °C. This 
experiment shows that no conversion from amorphous form to pure 
crystalline form is observed at this temperature, in contrast to a previous 








The work on moxidectin was devoted to shed some light on the behaviour 
of this important API, for which the patent literature reports the formation 
of different solvates but, up to date, only one X-ray solved structure was 
deposited in the CCDC (unsolvated forms). A systematic screening of the 
crystallisation behaviour of moxidectin in different solvent was undertaken, 
leading to the preparation of three distinct solvates. 
Single crystal X-ray diffractometric analysis of these solvates allowed to 
obtain important structural information on the location of the solvent 
molecules in the crystal, on the hydrogen bond networks formed intra- and 
intermolecularly and on the conformation of moxidectin. 
These results will be useful not only in the manufacturing processes of 
moxidectin, where the solvates may form during the crystallisation step, 
but even for the formulation of this API in the pharmaceutical form (tablets) 
and for issues related to its conservation. Moreover, the structural 
information will be useful for future studies on the polymorphism of this API. 
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8.3. Experimental section 
 
Moxidectin was generous gift by researcher group of Prof. Pattarino 
Franco, at Università del Piemonte Orientale “A. Avogardo”-Dipartimento 
di Scienze del Farmaco. 
 
Diffraction experiments were performed using Cu-Kα radiation (λ = 1.5418 
Å) on a vertical-scan Bruker AXS D8 Advance diffractometer in θ:θ mode, 
equipped with a Goebel Mirror and a Bruker Lynxeye linear Position 
Sensitive Detector (PSD), with the following optics: primary and secondary 
Soller slits, 2.3° and 2.5°, respectively; divergence slit, 0.1°; receiving slit, 
2.82°. Generator setting: 40 kV, 40 mA. The nominal resolution for the 
present set-up is 0.08° 2θ (FWHM of the α1 component) for the LaB6 peak 
at about 21.3° (2θ).  Variable-temperature X-ray powder diffraction (VT-
PXRD) experiments were performed on Moxi∙2iPrOH and Moxi∙2MeNO2. 
The experiments were carried out in a nitrogen atmosphere by coupling a 
custom-made sample heater, assembled by Officina Elettrotecnica di 
Tenno, Ponte Arche, Italy, to the instrumental set-up described above. A 
powdered microcrystalline sample was ground in an agate mortar and was 
deposited in the hollow of on a quartz zero-background plate framed by an 
aluminium skeleton. The data were acquired within a sensible, low-angle 
2θ range, heating the samples in situ in the temperature range 30-150°C, 
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Moxidectin (approximately 100 mg) was heated until dissolution in 
appropriate solvent. The resulting solution was kept at 0 – 5 °C until 
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9.1. General discussion 
 
APIs (Active Pharmaceutical Ingredients) play an important role in the 
control of public health. Pharmaceutical companies are directly involved in 
the synthesis, formulation and commercialisation of these fundamental 
compounds. 
Pharma companies employ several synthetic and technological strategies, 
during the development of APIs, with the aim to satisfy the market request. 
The continued expansion of the industrial APIs portfolio stimulates the 
pharma companies to develop new, alternative and cheap manufacturing 
processes in order to decrease the production costs by reducing the 
number of synthetic steps and increasing the overall yield.  
The manufacturing of APIs requires a consolidated and robust synthetic 
process suitable for the industrial productions. The process is selected 
after screening alternative synthetic routes, generally made in the R&D 
laboratory of the pharmaceutical industry. In this step several attempts are 
made in order to design and test the best synthetic route for the preparation 
of the API. The screening of reactions takes place by small scale 
experiments (1-10 g) giving useful information about the yield, the safety, 
the presence of byproducts and the overall costs. After the identification of 
the most efficient synthetic pathway, additional efforts are devoted to 
scrutiny the experimental conditions in order to increase the reaction scale, 
normally, to 50-200 grams. During this intermediate scale-up, reaction 
conditions such as the optimal concentration of reactants, reagents and 
catalysts, the correct temperature, and many other parameters, are 
optimised and used as necessary starting information for the future scale-
up from the R&D laboratory to the industrial plant. 
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During the development of the manufacturing process, additional 
information about the solid-state properties are needed. The presence of 
different polymorphic forms can lead to problems during the formulation of 
the API. The presence of polymorphs, solvates, hydrates or the presence 
of amorphous forms are then thoroughly investigated. 
 
During this PhD program, we studied a selection of APIs with the aim to 
discover new and alternative synthetic processes suitable for their 
industrial production. Exploration of synthetic methodologies led 
sometimes to identify unprecedented transformations, leading to 
interesting or unwanted compounds. Moreover, we explored the solid-state 
properties of APIs in order to identify the presence of polymorphic forms.  
In particular, during the PhD program, I focused my attention on different 
APIs and molecules: 
- Maropitant citrate hydrate (API) 
- Vanillin (Starting material) 
- DMAP molecule (Catalyst) 
- Gepirone hydrochloride (API) 
- Pirfenidone (API) 





In this PhD work we analysed several different and alternative synthetic 
approaches for the synthesis of maropitant citrate monohydrate, API for 
the treatment of emesis induced by motion sickness in animals.  
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The optimization of the procedure for the synthesis of the key intermediate 
(2S)-2-benzhydryl-3-quinuclidinone allowed to synthesise maropitant in 
high yield and reducing of byproducts. An alternative approach based on 
an alternative scheme of reductive amination and the preparation of a 
staring material through the Tscherniac-Einhorn reaction, led to an 
additional synthesis of this API. Comparison of the efficiency and the cost 
of the two processes led to the selection of the first one for the scale up of 
the manufacturing of maropitant. 
 
Vanillin oxidative fragmentation/amination 
During the investigation of the reactions of vanillin with secondary 
alkylamines, we observed an unprecedented reaction in aerobic 
conditions, generating 2,5-diamino-1,4-benzoquinones. This complex 
reaction appears to involve several steps and intermediates. The 
importance of this reaction resides in the possibility of this reaction to take 
place more frequently than expected, due to the widespread use of vanillin 
in food and in general in flavouring. The obtained intensely coloured 
orange-to-red products may be interesting as new pigments for foods or 
colourants for pharmaceutical products especially on the base of safety 





We reported the successful design and synthesis of a functionalised 
derivative of the well-known organocatalyst DMAP (4-(N,N-
dimethylamino)pyridine). The preparation of the functionalised DMAP (i.e.: 
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3-aminomethyl-4-(N,N-dimethylamino)pyridine) was attained in two steps, 
taking advantage of the strong electrophile generated in the Tscherniac-
Einhorn reaction to introduce an aminomethyl group on the DMAP 
molecule. The desired product is obtained in high yield and avoiding 
chromatographic separations, optimal prerequisites for a future large-scale 
preparation. The additional aminomethyl functional group has been 
exploited for the preparation of a silylated derivative, useful for grafting 
DMAP to an heterogenous inorganic support. 
Future development of this work will deal with the grafting of the 
functionalised DMAP to silica-based inorganic supports for the preparation 
of organic-inorganic hybrid catalysts and with the evaluation of their 
properties in heterogeneously catalysed acylation reactions. 
 
Gepirone Hydrochloride 
Gepirone hydrochloride belongs to the class of APIs known as azapirones 
and is used for the treatment of the major depressive disorder. In the 
literature, three polymorphs were detected by DSC but no structural 
information were reported, nor were information about the presence of 
additional polymorphs. Thermal analysis confirmed the presence of three 
forms of this API and we succeeded in isolating crystals of two of these 
forms, along with crystals of the free base. Single crystal X-ray diffraction 
analysis of these forms allowed to obtain detailed structural information. In 
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Pirfenidone 
In this work we investigated the solid-state properties of pirfenidone, API 
employed for the treatment of idiopathic pulmonary fibrosis. After a 
screening of solvents and mixtures thereof, a single crystal of this specific 
API, suitable for X-ray analysis, was obtained and the solid-state structure 
solved. Neither additional polymorphs were isolated, nor were adducts, 
solvates or inclusion compounds. The limited number of functional groups 




Moxidectin is an important API for the treatment of onchocerciasis, but 
limited informations are available on the solid-state forms of this 
compound. The patent literature claims the presence of different solvates, 
but to date only one (unsolvated) solid state structure has been deposited 
in international databases. In this PhD, we investigated the presence of 
additional polymorphs and, through a screening of solvents and mixture 
thereof, we were able to isolate three solvates (with ethanol, 2-propanol 
and nitromethane), then subjected to X-ray diffractometric analysis. 
 
During the PhD period, my personal contribution to these topics may be 
summarised as follows: 
 
- Proposal of different synthetic strategies for the synthesis of target 
compounds and selected intermediates thereof.  
- Starting material and reagents: I focused my attention on the 
choose of the correct starting material in relation with the 
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corresponding synthetic approach. Particular attention was 
dedicated to the cost, the availability and to safety issues related to 
the starting materials and reagents. 
- I run all test experiments, initially in small scale (1 – 10 g), with the 
aim to gain information about the reactions: yield, presence of by-
products, purity and safety. 
- I isolated the desired product and by-products in order to 
characterise them by different analytical instruments such as NMR, 
MS, HPLC.  
- I was directly involved in the optimisation of the reaction conditions 
in order to improve the efficiency of each step. 
- I increased the synthetic scale from 10 to over 500 grams. In this 
step I identified issues and problems related to the scale-up 
procedure such as temperature control, stirring and work-up 
conditions. 
- I completed the purification of the target compound through 
crystallisation processes in order to increase the purity of the final 
compound and to reach the purity required by regulatory agencies.  
- Moreover, I screened many conditions for the crystallization of APIs 
with the aim to obtain suitable crystals for the X-ray analysis and to 
identify the presence of polymorphic forms of a specific API. 
- Finally, I was directly involved in the writing of internal reports, 
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In conclusion, in the PhD period I was able to expand my knowledge in the 
vast world of APIs. The identification of the synthetic process and costs are 
only two of the different driving forces leading to the identifications of a 
suitable synthetic process for the manufacturing of APIs. Moreover, the 
solid-state properties play a central role during the production of the API. 
The presence of different crystalline forms can raise problems during the 
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